process for preparing a compound and compounds

专利摘要:
PROCESS FOR PREPARING A COMPOUND AND COMPOUNDS The present invention relates to a process for preparing a pyrazole compound of Formula V, which comprises cyclizing an α,β-unsaturated hydrazone substituted carbonyl compound of Formula IV, by reaction with a suitable reagent, for example a reducing agent, an organometallic reagent or a nucleophilic reagent. Formula V compounds are versatile reaction tools for the preparation of fine chemicals derived from pyrazole. The present invention also relates to the pyrazole compounds of Formulas Va, Vb, Vc and VI.
公开号:BR112016030863B1
申请号:R112016030863-8
申请日:2015-07-30
公开日:2021-05-04
发明作者:Birgit Gockel；Daniel Saelinger；Sebastian Soergel；Michael Rack
申请人:Basf Se；
IPC主号:

专利说明:

FIELD OF THE INVENTION
[001] The present invention relates to a process for the preparation of a pyrazole compound, according to the following reaction sequence:

[002] In particular, the present invention relates to a process for preparing a pyrazole compound of Formula V, which comprises the cyclization of an α,β-unsaturated hydrazone-substituted carbonyl compound of Formula IV by reaction with a suitable reagent, for example a reducing agent, an organometallic reagent or a nucleophilic reagent (step (c)). The process may further comprise the preparation of the α,β-unsaturated carbonyl compound with the hydrozone of Formula IV by reacting an α,β-unsaturated carbonyl compound of Formula III, which contains a leaving group at the β position, with a hydrazone compound of Formula II (step (b)), and preparing said hydrazone compound of Formula II by reacting a carbonyl compound of Formula I with hydrazine (step (a)).
[003] The process of the present invention may further comprise the steps of converting certain 4-substituted pyrazole compounds with activated 4-pyrazole carboxylic acid derivatives, according to the following reaction sequence:

In particular, the process of the present invention may optionally further comprise converting a pyrazole compound of Formula Va, which comprises an ester group at the 4-position, or a pyrazole compound of Formula Vb, which comprises a group cyano at the 4-position, in a 4-pyrazole carboxylic acid compound of Formula Vc (step (d)). In addition, the process may further comprise converting a 4-pyrazole carboxylic acid compound of Formula Vc to an activated 4-pyrazole carboxylic acid derivative of Formula VI (step (e)).
[005] The process of the present invention may further comprise the step of converting 4-activated pyrazole carboxylic acid derivatives into 4-pyrazole N-(het)arylamide compounds, which are known as the pesticide active compounds, of according to the following reaction:

[006] In particular, the process may further comprise the step of reacting an activated 4-pyrazole carboxylic acid derivative of Formula VI with a suitable N-(het)arylamine compound of Formula VII to provide an N-compound. Formula VIII 4-pyrazole (het)arylamide (step (f)).
[007] The present invention also relates to the novel pyrazole compounds of Formulas Va, Vb, Vc and VI. BACKGROUND OF THE INVENTION
[008] The pyrazole compounds, in particular the carboxylic acid derivatives of 4-pyrazole, such as the esters, nitriles, acids and activated acid derivatives, are versatile intermediate compounds for the preparation of fine chemicals derived from pyrazole, such as compounds in the pharmaceutical or agrochemical field. In particular, the compounds are versatile intermediate compounds for the preparation of pesticides derived from pyrazole, such as the 4-pyrazole N-(het)arylamide compounds, which are known to be especially useful for combating invertebrate pests (see publications WO 2009/027393, WO 2010/034737, WO 2010/034738 and WO 2010/112177). Of special interest are pyrazole compounds and 4-pyrazole carboxylic acid derivatives, which are substituted with a nitrogen atom and optionally also substituted at the 3 and/or 5 position, as also pesticides derived from pyrazole including the 4-pyrazole amide compounds mentioned above often comprise the pyrazole moieties, which are substituted accordingly.
[009] In view of the above, there is a need for a process for the preparation of the N-substituted pyrazole compounds and, optionally, further their conversion into pyrazole derivative pesticides. A special problem accompanying the preparation of N-substituted pyrazole compounds is regioselectivity, if the substituents are present at the 3 and/or 5 position of the pyrazole ring, especially if a substituent is present at the 3 position but not at the 5-position, if a substituent is present at position 5 but not at position 3, or if different substituents are present at position 3 and 5. Consequently, there is a special need for a process for the regioselective preparation of the N-substituted pyrazole compounds , which have a substituent at position 3 or at position 5 or different substituents at position 3 and 5 of the pyrazole ring. In view of the preparation of 4-pyrazole N-(het)arylamide compounds as pesticides, such a process should be especially suitable for obtaining the regioselectivity of N-substituted 4-pyrazole carboxylic acid derivatives having a substituent in the 3-position or 5-position or different substituents at 3- and 5-position of the pyrazole ring.
[010] It is observed that the numbering of the atoms of an N-substituted pyrazole compound is usually as follows.

[011] The positions of the substituents are indicated by the same numbers. The substituent on the nitrogen atom is usually referred to as the N-substituent rather than as the 1-position substituent, although this is also suitable. The 2-position, i.e. the second nitrogen atom of the N-substituted pyrazole compounds, is normally unsubstituted. In contrast, each of positions 3, 4 and 5 can be substituted.
[012] Mainly there are two known processes for the preparation of N-substituted 4-pyrazole carboxylic acid derivatives, which are substituted with 3 and/or 5.
[013] First, such N-substituted 4-pyrazole carboxylic acid derivatives can be prepared by reacting an α,β-unsaturated carbonyl compound, for example, an α,β-unsaturated ketone, which contains a leaving group at the β position, with a hydrazine derivative, which has a substituent on one of the two nitrogen atoms. In view of the fact that the substituted hydrazine derivative comprises two amino groups, which are often very similar in terms of their nucleophilic reactivity, usually two regioisomers of the desired N-substituted pyrazole compound are obtained as the nitrogen atom substituted or the unsubstituted nitrogen atom of the hydrazine derivative may react. Reactions, in which substituted hydrazine derivatives are used in the form of salts, have previously been described, for example, in publications JP 2007/326784, WO 2010/142628 and WO 2012/019015, and in reactions, in which hydrazine derivatives substituted monoprotected, have been described in publication WO 2012/019015. However, the problem of regioselectivity in terms of the 3/5 substitution pattern of the resulting N-substituted 4-pyrazole carboxylic acid derivatives could not be solved.
[014] Second, N-substituted 4-pyrazole carboxylic acid derivatives, which are substituted with 3 and/or 5, can be prepared by reacting an α,β-unsaturated carbonyl compound, e.g. an α,β-unsaturated ketone, which contains a leaving group at the β position, with hydrazine and then N-alkylation of the resulting pyrazole derivative. Due to the tautomer of the pyrazole compound, which is obtained as an intermediate, usually two regioisomers of the desired N-substituted pyrazole compound are obtained after alkylation. Such reaction sequences, for example, have been described in Heterocycles 2000, 2,775, Liebigs Analen der Chemie 1985, 794, or Journal of heterocyclic Chemistry 1985, 1109.
[015] A process for the regioselective preparation of N-substituted 4-pyrazole carboxylic acid derivatives, which are substituted with 3 or substituted with 3 and 5 with different substituents, was published by Glorius et al., in Angew. Chem. Int. Ed. 2010, 7790 and Green Chem. 2012, 14, 2193. Said process is carried out by reacting an enamine compound with an excess of a suitable nitrile compound in the presence of stoichiometric or catalytic amounts of copper.
[016] Although the regioselective process provides the N-substituted 4-pyrazole carboxylic acid derivatives, which are substituted with 3 or substituted with 3 and 5 with different substituents, the process is disadvantageous in that copper is involved as a heavy metal and an excess of at least three equivalents of the nitrile compound must be used, so the process is not ecological and not economical. Furthermore, the process has not been described for HCN as a nitrile compound, most likely due to the fact that HCN polymerizes under the reaction conditions, so that a cyclization reaction with the enamine compound would not occur, according to the reaction scheme above. As a consequence, N-substituted 4-pyrazole carboxylic acid derivatives, which are substituted with 5, but not substituted with 3 obviously cannot be obtained according to the process described by Glorius et al. BRIEF DESCRIPTION OF THE INVENTION
[017] In view of the above, it is an object of the present invention to provide a process for the preparation of N-substituted pyrazole compounds and, optionally, further their conversion into pyrazole-derived pesticides. In particular, it is an object to provide a process for the preparation of N-substituted pyrazole compounds, which are substituted, for example, at the 3 and/or 5 position and/or at the 4 position, wherein these substituents may be identical or different. , preferably different.
[018] It is another object of the present invention to provide a process for the regioselective preparation of N-substituted pyrazole compounds, which are substituted with 3 and/or 5. In particular, it is an object to provide regioselective access to a variety of pyrazole compounds. N-substituted pyrazoles, which are substituted with 3, substituted with 5 or substituted with 3 and substituted with 5 by different substituents, and preferably substituted with 5 but not substituted with 3.
[019] It is yet another object of the present invention to provide a process for the regioselective preparation of N-substituted 4-pyrazole carboxylic acid derivatives, for example, the esters or nitriles, which are substituted with 3 and/or 5. In In particular, it is an object to provide regioselective access to a variety of N-substituted 4-pyrazole carboxylic acid derivatives, which are substituted with 3, substituted with 5 or substituted with 3 and substituted with 5 by different substituents and, preferably, replaced with 5, but not replaced with 3.
[020] In relation to the above objects, another object is to provide a process that can be performed from readily available and inexpensive starting materials. Furthermore, it is an object related to the objects mentioned above to provide a process that is economical in terms of yields and quantities of reactants, which are reacted with each other. Furthermore, it is an object in relation to the objects mentioned above to provide a process, which is suitable for a technical scale.
[021] It is yet another object of the present invention to provide a process that still allows the supply of free N-substituted 4-pyrazole carboxylic acids and their activated derivatives, wherein said compounds, preferably, are substituted with 3 and/or 5, for example, substituted with 3, substituted with 5 or substituted with 3 and 5 by different substituents, and particularly preferably substituted with 5, but not substituted with 3.
[022] It is yet another object of the present invention to provide a process that further allows the provision of N-substituted 4-pyrazole amides, in which the pyrazole portion is preferably substituted with 3 and/or 5, e.g. with 3, substituted with 5 or substituted with 3 and 5 by different substituents, and especially preferably substituted with 5 but not substituted with 3.
[023] Furthermore, it is an object of the present invention to provide the N-substituted 4-pyrazole carboxylic acid derivatives, for example, the esters or nitriles, N-substituted 4-pyrazole carboxylic acids and their activated derivatives which, in in each case, they can be substituted with 3 and/or 5, for example, substituted with 3, substituted with 5 or substituted with 3 and 5 by different substituents, and preferably substituted with 5, but not substituted with 3. In particular, it is an object to provide N-substituted 4-pyrazole carboxylic acid derivatives, N-substituted 4-pyrazole carboxylic acids and their activated derivatives, which have specific N-substituents and specific substituents at position 5, but are unsubstituted at position 3, since such pyrazole compounds are suitable for the preparation of 4-pyrazole N-(het)arylamide compounds with an exceptionally high pesticidal activity.
[024] The above objects are achieved through the processes and compounds described in detail in the claims and hereafter. DETAILED DESCRIPTION OF THE INVENTION
[025] In one aspect, the present invention relates to the preparation of a pyrazole compound of Formula V or a stereoisomer, tautomer or N-oxide thereof.
- comprising the step of cyclizing an α,β-unsaturated hydrozone-substituted carbonyl compound of Formula IV
- by reacting with a reagent comprising an R6 group, - wherein: - R1 is selected from H, halogen, CN, NO2, C1 C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, where the C atoms are unsubstituted, may be partially or fully halogenated, or may be substituted with 1, 2 or 3 identical or different Rx substituents; - ORa, SRa, C(Y)ORc, S(O)mRd, S(O)mY1Rd, NReRf, C(Y)NRgRh, heterocyclyl, hetaryl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl and aryl, where as cyclic moieties can be unsubstituted or substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the radicals Ry and Rx; - R2 is selected from H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, in which the C atoms can be unsubstituted, can be partially or fully halogenated or can be substituted with 1, 2 or 3 identical or different Rx substituents; - C(Y)ORc, C(Y)NRgRh, heterocyclyl, hetaryl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl and aryl, where the cyclic moieties can be unsubstituted or can be substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the radicals Ry and Rx; and - R3 is selected from H, halogen, CN, NO2, C1C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, where the C atoms may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1, 2 or 3 identical or different Rx substituents; - ORa, SRa, C(Y)ORc, S(O)mRd, S(O)mY1Rd, NReRf, C(Y)NRgRh, heterocyclyl, hetaryl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl and aryl, where as cyclic moieties can be unsubstituted or can be substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the radicals Ry and Rx; - and wherein: - R4 and R5, independently of each other, are selected from H, NO2, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, where the C atoms may be unsubstituted, may be partially or fully halogenated or may be substituted with 1, 2 or 3 identical or different Rx substituents; - C1-C10 haloalkyl, C1-C4 alkoxy-C1-C10 alkyl, in which the C atoms can be unsubstituted, or partially or fully substituted with identical or different Ry substituents; - C(Y)ORc, C(Y)NRgRh, C(Y)NRiNReRf, C1-C5 alkylene-ORa, C1-C5 alkylene-CN, C1-C5 alkylene-C(Y)ORc, C1-C5 alkylene-NReRf , C1-C5 alkylene-C(Y)NRgRh, C1-C5 alkylene-S(O)mRd, C1-C5 alkylene-S(O)mNReRf, C1-C5 alkylene-NRiNReRf; - heterocyclyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, hetaryl, aryl, heterocyclyl-C1-C5 alkyl, C3-C10 cycloalkyl-C1-C5 alkyl, C3-C10 cycloalkenyl-C1-C5 alkyl, hetaryl C1-C5 alkyl, aryl C1-C5 alkyl, where the cyclic moieties may be unsubstituted or may be substituted with 1, 2, 3, 4 or 5 identical or different Ry substituents; - -DE groups, in which: - D is a direct bond, C1-C6 alkylene, C2-C6 alkenylene or C2-C6 alkynylene, where the carbon chains can be partially or fully substituted with Rn and - E is a carbon or non-aromatic 3- to 12-membered heterocycle, which may contain 1, 2, 3 or 4 heteroatoms selected from N-R1, O and S, where S may be oxidized, which carbo or heterocycle may be partially or fully substituted with Rn; - and - groups -A-SOm-G, wherein: - A is C1-C6 alkylene, C2-C6 alkenylene and C2-C6 alkynylene, wherein the C atoms may be unsubstituted, or partially or fully substituted with Rp, and -G is C1-C4 haloalkyl or C3-C6 cycloalkyl which may be halogenated; - or - R4 and R5 together with the carbon atom to which they are attached form a non-aromatic 3- to 12-membered carbo or heterocycle, which heterocycle may contain 1, 2, 3, 4 or 5 heteroatoms selected from N- R1, O and S, where S can be oxidized and which carbo or heterocycle can be partially or fully substituted with Rj; - and wherein: - R6 is selected from H, CN, C1-C6 fluoroalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl-C1-C2 alkyl , C3-C6 cycloalkenyl, C3-C6 cycloalkenyl-C1-C2 alkyl, heterocyclyl, heterocyclyl-C1-C2 alkyl, aryl, aryl-C1-C2 alkyl, hetaryl, hetaryl-C1-C2 alkyl, wherein the carbon chains or cyclic moieties may be unsubstituted, partially or fully substituted with identical or different Rx substituents; - ORa, Sra, NReRf and - groups of general formula (i)
- and in which: - Ra, Rb, independently of one another, are selected from H, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C3-C6 haloalkyl, C3-C6 cycloalkenyl , C3-C6 cycloalkenylmethyl, C3-C6 halocycloalkenyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy-C1-C4 alkyl, heterocyclyl, heterocyclyl-C1-C4 alkyl, aryl, hetaryl, aryl C1-C4 alkyl and hetaryl C1-C4 alkyl, wherein the cyclic moieties may be unsubstituted or may be substituted with 1, 2, 3, 4 or 5 substituents which, independently of one another, are selected from halogen, CN, C(O)NH2, NO2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; - Rc is selected from H, C1-C10 alkyl, C1-C10 haloalkyl, C3-C10 cycloalkyl, C3-C10 cycloalkylmethyl, C3-C10 halocycloalkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenylmethyl, C3-C6 halocycloalkenyl, alkenyl C2-C10, C2-C10 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy-C1C4 alkyl, heterocyclyl, heterocyclyl-C1-C4 alkyl, aryl, heteroaryl, aryl C1-C4 alkyl and hetaryl C1-C4 alkyl, where the ring in the last six mentioned radicals may be unsubstituted or may be substituted with 1, 2, 3, 4 or 5 substituents which, independently of one another, are selected from halogen, CN, C(O)NH2, NO2, C1 alkyl -C4, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; or - Rc together with the C(Y)O group forms a [C(Y)O]-NR4+, [C(Y)O]-Ma+ or [C(Y)O]-%Mea2+ salt, where Ma is an alkali metal and Mea is an alkaline earth metal, and wherein the R substituents on the nitrogen atom, independently of one another, are selected from H, C1-C10 alkyl, phenyl and phenyl-C1-C4 alkyl; - Rd is selected from C1-C4 alkoxy, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C3C6 halocycloalkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenylmethyl, C3-C6 haloalkenyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy-C1-C4 alkyl, heterocyclyl, heterocyclyl-C1-C4 alkyl, aryl, hetaryl, aryl C1-C4 alkyl and hetaryl C1-C4 alkyl, wherein the cyclic moieties may be unsubstituted or may be substituted with 1, 2, 3, 4 or 5 substituents which, independently of one another, are selected from halogen, CN, C(O)NH2, NO2, C1-alkyl C4, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; - Re, Rf, independently of one another, are selected from H, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C3-C6 halocycloalkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenylmethyl , C3-C6 halocycloalkenyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy-C1-C4 alkyl, C1-C4 alkylcarbonyl, C1-C4 haloalkylcarbonyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylsulfonyl , heterocyclyl, heterocyclyl-C1-C4 alkyl, heterocyclylcarbonyl, heterocyclyl C1-C4-sulfonyl, aryl, arylcarbonyl, arylsulfonyl, hetaryl, hetarylsulfonyl, aryl C1-C4 alkyl and hetaryl C1-C4 alkyl, where the cyclic moieties may not be substituted or they can be substituted with 1, 2, 3, 4 or 5 substituents which, independently of one another, are selected from halogen, CN, C(O)NH2, NO2, C1-C4 alkyl, C1-C4 haloalkyl, C1 alkoxy -C4 and C1-C4 haloalkoxy; or - Re and Rf together with the N atom to which they are attached form a 5- or 6-membered saturated or unsaturated heterocycle, which may comprise another heteroatom selected from O, S and N as a ring member atom and wherein the heterocycle may be unsubstituted or may be substituted with 1, 2, 3, 4 or 5 substituents which, independently of one another, are selected from halogen, CN, C(O)NH2, NO2, C1-alkyl C4, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; - Rg, Rh, independently of one another, are selected from H, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C3-C6 cycloalkenyl, C3-C6 haloalkenyl, C2-C4 alkenyl , C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy-C1-C4 alkyl, heterocyclyl, heterocyclyl-C1-C4 alkyl, aryl, hetaryl, aryl C1-C4 alkyl and hetaryl C1-C4 alkyl, wherein the portions cyclics can be unsubstituted or can be substituted with 1, 2, 3, 4 or 5 substituents which, independently of one another, are selected from halogen, CN, C(O)NH2, NO2, C1-C4 alkyl, C1 haloalkyl -C4, C1-C4 alkoxy and C1-C4 haloalkoxy; - Ri is selected from H, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C3-C6 halocycloalkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenylmethyl, C3-C6 halocycloalkenyl, alkenyl C2-C4, C2-C4 haloalkenyl, C2-C4 alkynyl, C1-C4 alkoxy-C1-C4 alkyl, aryl, aryl C1-C4 alkyl, wherein the aryl ring may be unsubstituted or may be substituted with 1, 2, 3, 4 or 5 substituents which, independently of one another, are selected from halogen, CN, C(O)NH2, NO2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; - Rj is halogen, OH, CN, C(O)NH2, NO2, C1-C10 alkyl, C1-C10 haloalkyl, C1-C10 alkoxy, C1-C10 haloalkoxy, benzyloxy, S(O)mRk, C3-C6 cycloalkyl , or a 3 to 6 membered heterocycle, which may contain 1 or 2 heteroatoms selected from N-R1, O and S, where S may be oxidized, whose Rj groups are unsubstituted or partially or fully substituted with Rm, and wherein two Rj groups attached to the same or adjacent ring atoms together may form a 3- to 6-membered carbo or heterocyclic ring, which heterocycle may contain 1 or 2 heteroatoms selected from N-R1, O and S, in that S can be oxidized, which cycles can be partially or totally replaced with radicals Rm; - Rk is H, C1-C4 alkyl, C1-C4 haloalkyl or C3-C6 cycloalkyl, which cycle can be partially or fully substituted by R1; - R1 is H, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkylcarbonyl, or C1-C4 alkoxycarbonyl; - Rm is halogen, OH, CN, C(O)NH2, NO2, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy or S(O)mRk; - Rn is halogen, CN, C(Y)ORc, C(O)NH2, NO2, C1-C2 alkyl, C1-C4 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-cycloalkenyl C6, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxy-C1-C4 alkyl, C1-C4 alkylidene or S(O)mRo, two adjacent groups Rn, together with the atoms to which they are attached, can form a 3- to 8-membered carbo or heterocycle, which can contain 1, 2, 3 or 4 heteroatoms selected from N-R1, O and S, where S can be oxidized, whose cyclic Rn moieties can be replaced with halogen, Ro or R1; - Ro is H, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, or C1-C4 alkoxy; - Rp is halogen, CN, C(O)NH2, NO2, C1-C2 alkyl, C1-C2 haloalkyl, C3-C6 cycloalkyl, C1-C4 alkoxy or C1-C2 haloalkoxy, or two Rp groups together can form a 3 to 6 membered carbo or heterocyclic ring whose heterocycle contains 1 or 2 heteroatoms selected from N-R1, O and S, where S can be oxidized, whose carbo or heterocyclic ring is unsubstituted or partially or fully substituted with Rq groups; - Rq is halogen, CN, C(O)NH2, NO2, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C1-C4 alkoxy or C1-C4 haloalkoxy; - Rr and Rs, independently of each other, are selected from Rb, ORc1 and NRgRh; - Rc1 is C1-C10 alkyl, C1-C10 haloalkyl, C3-C10 cycloalkyl, C3-C10 cycloalkylmethyl, C3-C10 halocycloalkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenylmethyl, C3-C6 halocycloalkenyl, C2-C10 alkenyl, haloalkenyl C2-C10, C2-C4 alkynyl, C1-C4 alkoxy-C1-C4 alkyl, heterocyclyl, C1-C4 heterocycloalkyl, aryl, hetaryl, aryl C1-C4 alkyl or hetaryl C1-C4 alkyl, wherein the ring in the last six radicals mentioned may be unsubstituted or may be substituted with 1, 2, 3, 4 or substituents which, independently of one another, are selected from halogen, CN, C(O)NH2, NO2, C1-C4 alkyl, C1-haloalkyl C4, C1-C4 alkoxy or C1C4 haloalkoxy; - Rt is H or Ra; - Rx is halogen, CN, C(Y)ORc, C(Y)NRgRh, NO2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, S(O)mRd, S( O)mNReRf, C1-C5 alkylene-NHC(O)ORc, C1-C10 alkylcarbonyl, C1-C4 haloalkylcarbonyl, C1-C4 alkoxycarbonyl, C1-C4 haloalkoxycarbonyl, C3-C6 cycloalkyl, 5- to 7-membered heterocyclyl, 5-membered heteroaryl or 6-membered, aryl, C3-C6 cycloalkoxy, 3 to 6-membered heterocyclyloxy, or aryloxy, in which the cyclic moieties may be unsubstituted or may be substituted with 1, 2, 3, 4 or 5 Ry radicals; and - Ry is selected from halogen, CN, C(Y)ORc, C(Y)NRgRh, NO2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1C4 haloalkoxy, benzyloxymethyl, S(O) mRd, S(O)mNReRf, C1-C4 alkylcarbonyl, C1-C4 haloalkylcarbonyl, C1-C4 alkoxycarbonyl, C1-C4 haloalkoxycarbonyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2 alkynyl -C4 and C1-C4 alkoxy-C1-C4 alkyl; - and where: - Y is the O or S; - Y1 is O, S, or N-R1a; - R1a is H, C1-C10 alkyl, C3-C12 cycloalkyl, aryl or hetaryl; and - m is 0, 1 or 2.
[026] Preferably, Formula IV is to be understood not only as encompassing the compounds as such, but also as capping salts, stereoisomers, tautomers or N-oxides of the compounds of Formula IV.
[027] The process as defined above is suitable to provide a variety of N-substituted pyrazole compounds of Formula V, which can be further converted to provide the pyrazole derived pesticides.
[028] Furthermore, it has surprisingly been found that the process is suitable for regioselectively preparing a variety of N-substituted pyrazole compounds, which are substituted with 3 or 5 or substituted with different substituents at position 3 and 5. In particular, the pattern of substitution of the compounds of Formula IV pre-defines the substitution pattern of the resulting N-substituted pyrazole compounds, so that the problem of regioselectivity can be completely avoided. The compound of Formula IV can be selected as such, that a variety of substituents can be carried out at position 3 and/or 5, as well as at position 4 of the N-substituted pyrazole compounds. In this context, it has also been found that N-substituted 4-pyrazole carboxylic acid derivatives, which are substituted with 3 or 5 or substituted with different substituents at position 3 and 5, can be regioselectively obtained by means of the process, according to the present invention.
[029] The process provides the N-substituted pyrazole compounds of Formula V in high yields based on the amounts of the compounds of Formula IV.
[030] Furthermore, it is an advantage of the process that compounds of Formula IV can be obtained from readily available and inexpensive starting materials. In particular, it is an advantage that compounds of Formula IV can be obtained by reacting α,β-unsaturated carbonyl compounds of Formula III, which contain a leaving group at the β-position, with hydrazone compounds of Formula II , wherein the α,β-unsaturated carbonyl compounds of Formula III are readily commercially available or by means of the methods known in the art and the hydrazone compounds of Formula II easily can be obtained by reaction with commercially available carbonyl compounds of Formula I with hydrazine. This will be outlined in more detail below. By varying the Formula I carbonyl compounds and the Formula III α,β-unsaturated carbonyl compounds, therefore, a variety of Formula II, IV and V compounds can easily be obtained.
[031] Furthermore, compounds of Formula V can still be converted to pesticides derived from pyrazole. For example, if the pyrazole compound of Formula V is a pyrazole compound of Formula Va or Vb with an ester or a cyano group at the 4-position, said compound can easily be converted to the corresponding 4-pyrazole carboxylic acid compound of Formula Vc . Alternatively, such 4-pyrazole carboxylic acid compounds of Formula Vc can be directly obtained from the suitable compounds of Formula IV. From the Formula Vc 4-pyrazole carboxylic acid compound, the Formula VI activated 4-pyrazole carboxylic acid derivatives can be obtained by standard activation processes. The Formula VI compounds, therefore, can be converted to the Formula VIII 4-pyrazole N-(het)arylamide compounds, which can represent the highly active pesticides.
[032] In view of the above, certain preferred embodiments of the present invention relate to a process, wherein the α,β-unsaturated hydrazone substituted carbonyl compound of Formula IV
- is prepared through the reaction of an α,β-unsaturated carbonyl compound of Formula III
- with a hydrazone compound of Formula II
- where: - X is an output group; - and R1, R2, R3, R4 and R5 are as defined above.
[033] Furthermore, certain more preferred embodiments of the present invention relate to a process, in which the above hydrazone compound of Formula II is prepared by reacting a carbonyl compound of Formula I
- with the hydrazine or a salt thereof, - wherein R4 and R5 are as defined above.
[034] Preferably, Formulas I, II, III and IV are to be understood not only as encompassing the compounds as such, but also as salts, stereoisomers, tautomers or N-oxides of these compounds. However, N-oxides are naturally only possible if a nitrogen atom is present in the compounds.
[035] In view of the above, certain preferred embodiments of the present invention further relate to a process, wherein the compound of Formula V is a compound of Formula Va or Vb
- and wherein said compound of Formula Va or Vb is converted to a compound of Formula Vc
- where R 2 , R 3 , R 4 , R 5 and R 6 are as defined above, - and where R c in Formula Va is C 1 -C 4 alkyl or aryl C 1 -C 4 alkyl.
[036] Preferably, Formulas Va, Vb and Vc are to be understood not only as encompassing the compounds as such, but also as capping salts, stereoisomers, tautomers or N-oxides of these compounds.
[037] Furthermore, certain preferred embodiments of the present invention relate to a process, wherein a compound of Formula Vc is converted to a compound of Formula VI
- where X1 is a leaving group, and where R2, R3, R4, R5 and R6 are as defined above.
[038] With regard to X1, it is observed that X1 can be any leaving group, preferably a leaving group, which is suitable for amide coupling reactions.
[039] For example, X1 can be a leaving group, which is based on a peptide coupling reagent. Suitable peptide coupling reagents are described by Han et al., in Tetrahedron 60 (2004) 2,447-2,467. In this regard, N,N'-bis(2-oxo-3-oxazolidinyl)-phosphinic chloride (BOP-Cl) and O-(7-azabenzotriazol-1-yl)-1,1,hexafluorophosphate, 3,3-tetramethyluronium (HATU) are preferably in accordance with the present invention.
[040] In addition, X1 can be a leaving group selected from active esters, azide and halogens.
[041] Preferably, X1 is selected from halogen, N3, p-nitrophenoxy and pentafluorophenoxy, and particularly preferably is halogen such as Cl.
[042] Preferably, Formula VI again is to be understood not only as encompassing the compounds as such, but also as capping salts, stereoisomers, tautomers or N-oxides of these compounds.
[043] Furthermore, certain more preferred embodiments of the present invention relate to a process, wherein the compound of Formula VI above is converted to a compound of Formula VIII
- by reacting with a compound of Formula VII
- wherein R2, R3, R4, R5 and R6 are as defined above, and wherein: - U is N or CRU; - RP1, RP2, RP3 and RU, independently of each other, are selected from H, halogen, C1-C4 alkyl, C1-C3 haloalkyl, C1-C4 alkoxy, C1-C3 haloalkoxy, C1-C4 alkylthio, C1-C1-haloalkylthio C3, C1C4 alkylsulfinyl, C1-C3 haloalkylsulfinyl, C1-C4 alkylsulfonyl, C1-C3 haloalkylsulfonyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl and C1-C4 alkoxy C1-C4 alkyl; and - R1N is H, CN, C1-C10 alkyl, C1-C10 haloalkyl, C3C10 cycloalkyl, C3-C10 halocycloalkyl, C1-C4 alkoxyC1-C4 alkyl, C2-C10 alkenyl, C2-C10 haloalkenyl, C2-alkynyl C10, C3-C10 haloalkynyl, C1-C5-CN alkylene, ORa, C1-C5 alkylene-ORa, C(Y)Rb, C1-C5 alkylene-C(Y)Rb, C(Y)ORc, C1-C5 alkylene -C(Y)ORc, S(O)2Rd, NReRf, C1-C5 alkylene-NReRf, C(Y)NRgRh, C1-C5 alkylene-C(Y)NRgRh, S(O)mNReRf, C(Y)NRiNReRf , C1-C5 alkylene-S(O)2Rd, C1-C5 alkylene-S(O)mNReRf, C1-C5 alkylene-C(Y)NRiNReRf, aryl, heterocyclyl, hetaryl, C1-C5 aryl alkyl, C3-C10 cycloalkyl -C1-C5 alkyl, heterocyclyl-C1-C5 alkyl or hetaryl C1-C5 alkyl, wherein the cyclic moieties may be unsubstituted or may be substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the radicals Ry and Rx.
[044] Preferably, Formulas VI and VIII again are to be understood not only as encompassing the compounds as such, but also as capping salts, stereoisomers, tautomers or N-oxides of these compounds.
[045] In another aspect, the present invention relates to a compound of Formula Va or a salt, stereoisomers, tautomer or N-oxide thereof
- wherein: - R2 is CH3, R3 is H, R4 is CH(CH3)2, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is CHFCH3, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-CN-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-C(O)NH2-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 and R5 together are CH2CH2CF2CH2CH2, and R6 is H; - and wherein: - Rc is C1-C4 alkyl or aryl C1-C4 alkyl, or wherein Rc together with the C(O)O group forms a [C(O)O]-NR4+ salt, [C( O)O]-Ma+ or [C(O)O]-%Ma2+, where Ma is an alkali metal and Mea is an alkaline earth metal; and wherein the R substituents on the nitrogen atom, independently of one another, are selected from H, C1-C10 alkyl, phenyl and phenyl-C1-C4 alkyl.
[046] In yet another aspect, the present invention relates to a compound of Formula Vb or a salt, stereoisomers, tautomer or N-oxide thereof
- wherein: - R2 is CH3, R3 is H, R4 is CH(CH3)2, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is CHFCH3, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-CN-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-C(O)NH2-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 and R5 together are CH2CH2CF2CH2CH2, and R6 is H.
[047] The compounds of Formula Va and Vb represent the precursors of N-substituted 4-pyrazole carboxylic acids Vc, which in themselves represent the versatile reaction tools for the preparation of certain 4-N-(het)arylamide compounds. -pyrazole of Formula VIII, which are highly active pesticides.
[048] Thus, in another aspect, the present invention relates to a compound of Formula Vc or a salt, stereoisomer, tautomer or N-oxide thereof
- wherein: - R2 is CH3, R3 is H, R4 is CH(CH3)2, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is CHFCH3, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-CN-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-C(O)NH2-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 and R5 together are CH2CH2CF2CH2CH2, and R6 is H.
[049] The Formula Vc 4-pyrazole carboxylic acid compounds can easily be activated for a further amidation reaction to provide the Formula VIII 4-pyrazole N-(het)arylamide compounds.
[050] Thus, in yet another aspect, the present invention relates to a compound of Formula VI or a salt, stereoisomer, tautomer or N-oxide thereof
- wherein: - R2 is CH3, R3 is H, R4 is CH(CH3)2, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is CHFCH3, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-CN-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-C(O)NH2-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 and R5 together are CH2CH2CF2CH2CH2, and R6 is H; - and in which: - X1 is a leaving group which preferably is selected from halogen, N3, p-nitrophenoxy and pen-tafluorophenoxy and which particularly preferably is Cl.
[051] The compounds of Formula VI represent activated species that can be formed in situ or isolated after activation of the 4-pyrazole carboxylic acid compounds of Formula Vc and that can easily be converted to the N-(het)arylamide compounds of 4-pyrazole of Formula VIII by reacting it with a suitable N-(het)arylamine.
[052] Other embodiments of the present invention can be found in the claims, description and examples. It should be understood that the characteristics mentioned above and those to be illustrated further below the object of the present invention can be applied not only in the respective provided combination, but also in other combinations without departing from the scope of the present invention.
[053] In the context of the present invention, the terms used generically are each defined as follows.
[054] The term "compound(s), according to the present invention," in the context of compounds of Formulas I, II, III, IV, V, Va, Vb, Vc, VI, VII and VIII comprises the(s) ) compound(s) as well as stereoisomers, salts, tautomers or N-oxides. The term "compound(s) of the present invention" is to be understood as equivalent to the term "compound(s) according to the present invention".
[055] The N-oxides of the compounds of the present invention can only be obtained if the compounds contain a nitrogen atom, which can be oxidized. This is primarily the case for compounds of Formulas II, IV, V, Va, Vb, Vc, VI, VII and VIII, but not necessarily the case for compounds of Formulas I and III. Therefore, the term "compound(s)" in accordance with the present invention" will only encompass the stereoisomers, salts and tautomers of the compounds of Formulas I and III, if these compounds do not contain a nitrogen substituent, which would allow the formation of an N-oxide. The N-oxides can mainly be prepared by standard methods, for example, by the method described in Journal of Organometallic Chemistry 1989, 370, 17-31. However, according to the present invention, it is preferably that the intermediate compounds I, II, III and IV in the preparation of the compounds of Formula V are not present in the form of N-oxides. Furthermore, if it is desired to convert compounds of Formula Va or Vb to compounds of Formula Vc, or to convert compounds of Formula Vc to compounds of Formula VI, or to convert compounds of Formula VI to compounds of Formula VIII, also de preferably, the compounds are not present in the form of N-oxides. On the other hand, under certain reaction conditions, it is not possible to prevent the N-oxides from being formed, at least in an intermediate way.
[056] Stereoisomers of compounds of Formulas I, II, III, IV, V, Va, Vb, Vc, VI, VII and VIII will be present if the compounds contain one or more centers of chirality in the substituents. In this case, the compounds will be present in the form of different enantiomers or diastereomers, if more than one center of chirality is present. The compounds of the present invention encompass all possible stereoisomers, that is, single enantiomers or diastereomers, as well as mixtures thereof. With respect to the compounds of Formula V, it is observed that a center of chirality is also present in the generic Formula if the substituents R4, R5 and R6 are different from each other. Said center of chirality is newly formed when compounds of Formula V are prepared from compounds of Formula IV. In particular, the carbon atom hybridized with sp2, to which the R4 and R5 substituents are attached in the compounds of Formula IV, can be attacked by the reagent comprising the R6 group from two sides, so that mainly can be obtained two configurations in position resulting in carbon atoms hybridized with sp3. The two possible stereoisomers of the compounds of Formula V, V:SI-A and V:SI-B, which can be obtained according to the process according to the present invention, are illustrated below.

[057] Analogous stereoisomers for the compounds of Formula Va, Vb, Vc, VI and VIII are also possible. Thus, if the substituents R4, R5 and R6 are different from each other so that a center of quality is present, the generic Formulas V, Va, Vb, Vc, VI and VIII as used herein encompass two stereoisomers analogous to two stereoisomers as described above. For the sake of clarity, no distinction is made between the two stereoisomers of generic Formulas V, Va, Vb, Vc, VI and VIII throughout the specification. Instead, the group -CR4R5R6 is represented without any indication regarding the three-dimensional structure, but it should be understood that the generic Formulas V, Va, Vb, Vc, VI and VIII, in each case, encompass both possible stereoisomers, if the -CR4R5R6 group is chiral due to the different meanings of R4, R5 and R6.
[058] The geometric isomers of the compounds of the present invention are normally possible, if the compounds contain at least one carbon-carbon or carbon-nitrogen double bond, since the E and Z isomers of the compounds, therefore, may be gifts. The compounds of the present invention encompass all possible geometric isomers, i.e. the single E or Z isomers, as well as mixtures thereof. With respect to compounds of Formulas II, III and IV, it is observed that a carbon-carbon double bond and/or a carbon-nitrogen double bond is present in the generic Formula. As in each case, the E and Z isomers are both intended to be covered, the generic Formulas are represented with wavy lines to the substituents, indicating that the two substituents on an sp2 hybridized carbon atom may be present at each position. The possible E and Z isomers for the compounds of Formula II (ie the II: GI-A1 and II: GI-B1), III (ie the III:GI-A2 and III:GI-B2) and IV (ie, IV:GI-A1A2, IV:GI-B1A2, IV:GI-A1B2 and IV:GI-B1B2) are illustrated below.

[059] Therefore, if E and Z isomers are possible, the generic Formulas II, III and IV as used herein, in each case, are intended to cover all geometric isomers as illustrated above, which is indicated by the wavy lines for the substituents in the generic Formulas.
[060] The tautomers of the compounds of Formulas I, II, III, IV, V, Va, Vb, Vc, VI, VII and VIII include the keto-enol tautomers, imine-enamine tautomers, amide-imidic acid tautomers and the like. Such tautomerism is possible, for example, for generic Formulas I, II, III, IV and VIII (if R1N is H). Depending on the substituents, which are defined for the compounds of Formulas I, II, III, IV, V, Va, Vb, Vc, VI, VII and VIII, other tautomers can be formed. The compounds of the present invention encompass all possible tautomers.
[061] Depending on the acidity or basicity, as well as the reaction conditions, the compounds of Formula I, II, III, IV, V, Va, Vb, Vc, VI, VII and VIII may be present in the form of salts. Such salts will normally be obtained by reacting the compound with an acid if the compound has a basic functionality such as an amine, or by reacting the compounds with a base if the compound has an acidic functionality such as an acid group. carboxylic acid. For example, compounds of Formula Vb include the carboxylic acid salts of 4-pyrazole, in which the cation is derived from the base, with which the carboxylic acid of 4-pyrazole has been reacted to provide an anionic carboxylate. If a carboxylic acid group COOH is present in the form of a carboxylate, that anion can be referred to as [C(O)O]-, in which the negative charge is normally delocalized on the two oxygen atoms of the carboxylate group. On the other hand, the cationic charge of an ammonium cation, which can be formed from an amino group in the presence of an acid, is normally not delocalized.
[062] The cations, which derive from a base, with which the compounds of the present invention are reacted, for example, are the alkali metal cations Ma+, the alkaline earth metal cations Mea2+ or the ammonium cations NR4+, wherein the alkali metals preferably are sodium, potassium or lithium and the alkaline earth metal cations preferably are magnesium or calcium and wherein the R substituents of the NR4+ ammonium cation are preferably independently selected from H, C1-C10 alkyl, phenyl and phenyl-C1-C2 alkyl.
[063] The anions, which derive from an acid, with which the compounds of the present invention were reacted, for example, are chloride, bromide, fluoride, hydrogen sulfate, sulfate, dihydrogen phosphate, hydrogen phosphate, phosphate, nitrate, bicarbonate, carbonate, hexafluorosilicate, hexafluorophosphate, benzoate and the anions of C1-C4 alkanoic acids, propionate and butyrate.
[064] The compounds of the present invention may be in solid or liquid form. If the compounds are present as solids, the compounds may be amorphous or may exist in one or more other crystalline forms. The compounds of the present invention encompass mixtures of different crystalline forms of the respective compounds as well as their amorphous or crystalline salts.
[065] The organic portions mentioned in the above definitions of variables are - like the term halogen - collective terms for the individual lists of individual group members. The prefix Cn-Cm indicates, in each case, the possible number of carbon atoms in the group.
[066] The term "halogen" in each case means fluorine, bromine, chlorine or iodine, in particular, fluorine, chlorine or bromine.
[067] The term "alkyl" as used herein and in the alkyl portions of alkylamino, alkylcarbonyl, alkylthio, alkylsulfenyl, alkylsulfonyl and alkoxyalkyl indicates, in each case, a straight or branched chain alkyl group, usually containing from 1 to 10 carbon atoms, often from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms and in particular from 1 to 3 carbon atoms. Examples of an alkyl group are methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, iso-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3- methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dibutylmethyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2, 2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl.
[068] The term "haloalkyl", as used herein and in the haloalkyl portions of haloalkylcarbonyl, haloalkoxycarbonyl, haloalkylthio, haloalkylsulfonyl, haloalkylsulfinyl, haloalkoxy and haloalkoxyalkyl, indicates, in each case, a straight or branched chain alkyl group that usually contains from 1 to 10 carbon atoms, often from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, the hydrogen atoms of this group being partially or fully replaced with halogen atoms. The haloalkyl moieties are preferably selected from C1-C4 haloalkyl, more preferably from C1-C3 haloalkyl or C1-C2 haloalkyl, especially from C1C2 fluoroalkyl, such as fluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, and the like.
[069] The term "alkoxy" as used herein indicates, in each case, a straight or branched chain alkyl group that is attached through an oxygen atom and normally contains 1 to 10 carbon atoms, often from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms. Examples of an alkoxy group are methoxy, ethoxy, n-propoxy, iso-propoxy, n-butyloxy, 2-butyloxy, iso-butyloxy, tert-butyloxy and the like.
[070] The term "alkoxyalkyl", as used herein, refers to alkyl which generally comprises from 1 to 10, often from 1 to 4, preferably from 1 to 2 carbon atoms, where 1 carbon atom is substituted with an alkoxy radical which normally comprises from 1 to 4, preferably 1 or 2 carbon atoms, as defined above. Examples are CH2OCH3, CH2-OC2H5, 2-(methoxy)ethyl, and 2-(ethoxy)ethyl.
[071] The term "haloalkoxy", as used herein, in each case indicates a straight-chain or branched alkoxy group containing from 1 to 10 carbon atoms, often from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, where the hydrogen atoms in this group are partially or fully replaced with halogen atoms, especially fluorine atoms. The haloalkoxy moieties preferably include C1-C4 haloalkoxy, especially C1-C2 fluoroalkoxy, such as fluoromethoxy, difluoromethoxy, trifluoromethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2.2-difluoroethoxy, 2,2,2-trifluoroethoxy , 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy and the like.
[072] The term "alkylthio" (alkylsulfanyl: -S-alkyl)", as used herein, refers to a straight or branched chain saturated alkyl group containing 1 to 10 carbon atoms, preferably 1 to 4 carbon atoms, (= C1-C4 alkylthio), preferably from to 3 carbon atoms, which is bonded via a sulfur atom.
[073] The term "haloalkylthio", as used herein, refers to an alkylthio group as mentioned above, in which the hydrogen atoms are partially or fully replaced with fluorine, chlorine, bromine and/or iodine.
[074] The term "alkylsulfinyl" (alkylsulfoxy: C1-C6 alkyl-S (=O)-), as used herein, refers to a straight or branched chain saturated alkyl group (as mentioned above) containing from 1 to 10 carbon atoms, preferably 1 to 4 carbon atoms (= C1-C4 alkylsulfinyl), more preferably 1 to 3 carbon atoms bonded via the sulfur atom of the sulfinyl group at any position in the alkyl group .
[075] The term "haloalkylsulfinyl", as used herein, refers to an alkylsulfinyl group, as mentioned above, in which the hydrogen atoms are partially or fully replaced with fluorine, chlorine, bromine and/or iodine.
[076] The term "alkylsulfonyl" (alkyl-S(=O)2-), as used herein, refers to a straight or branched chain saturated alkyl group containing from 1 to 10 carbon atoms, preferably from 1 to 4 carbon atoms (= C 1 -C 4 alkylsulfonyl), preferably 1 to 3 carbon atoms, which is bonded via the sulfur atom of the sulfonyl group, at any position in the alkyl group.
[077] The term "haloalkylsulfonyl", as used herein, refers to an alkylsulfonyl group, as mentioned above, in which the hydrogen atoms are partially or fully replaced with fluorine, chlorine, bromine and/or iodine.
[078] The term "alkylcarbonyl" refers to an alkyl group as defined above, which is attached via the carbon atom of a carbonyl group (C=O) to the remainder of the molecule.
[079] The term "haloalkylcarbonyl" refers to an alkylcarbonyl group, as mentioned above, in which the hydrogen atoms are partially or fully replaced with fluorine, chlorine, bromine and/or iodine.
[080] The term "alkoxycarbonyl" refers to an alkyl group as defined above, which is attached via an oxygen atom to the remainder of the molecule.
[081] The term "haloalkoxycarbonyl" refers to an alkoxycarbonyl group, as mentioned above, in which the hydrogen atoms are partially or fully replaced with fluorine, chlorine, bromine and/or iodine.
[082] The term "alkenyl" as used herein indicates, in each case, a singly unsaturated hydrocarbon radical which normally contains from 2 to 10, often from 2 to 6, preferably from 2 to 4 carbon atoms , for example, vinyl, allyl (2-propen-1-yl), 1-propen-1-yl, 2-propen-2-yl, metalyl (2-methyl-prop-2-en-1-yl) , 2-buten-1-yl, 3-buten-1-yl, 2-penten-1-yl, 3-penten-1-yl, 4-penten-1-yl, 1-methylbut-2-en-1 -yl, 2-ethylprop-2-en-1-yl and the like.
[083] The term "haloalkenyl", as used herein, refers to an alkenyl group as defined above, in which the hydrogen atoms are partially or fully replaced with halogen atoms.
[084] The term "alkynyl" as used herein indicates, in each case, a singly unsaturated hydrocarbon radical which normally contains from 2 to 10, often from 2 to 6, preferably from 2 to 4 carbon atoms , for example, ethynyl, propargyl (2-propyn-1-yl), 1-propyn-1-yl, 1-methyl-prop-2-yn-1-yl), 2-butyn-1-yl, 3 -butyn-1-yl, 1-pentyn-1-yl, 3-pentyn-1-yl, 4-pentyn-1-yl, 1-methylbut-2-yn-1-yl, 1-ethylprop-2-yn -1-il and the like.
[085] The term "haloalkynyl", as used herein, refers to an alkynyl group as defined above, in which the hydrogen atoms are partially or fully replaced with halogen atoms.
[086] The term "cycloalkyl", as used herein and in the cycloalkyl portions of cycloalkoxy and cycloalkylmethyl indicates, in each case, a monocyclic cycloaliphatic radical that normally contains from 3 to 10 or from 3 to 6 carbon atoms, such as a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloepyl, cyclooctyl, cyclononyl and cyclodecyl or cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
[087] The term "halocycloalkyl", as used herein, and in the halocycloalkyl portions of halocycloalkoxy and halocycloalkylthio, in each case, means a monocyclic cycloaliphatic radical which normally contains from 3 to 10 carbon atoms or from 3 to 6 carbon atoms. C, in which at least one, for example 1, 2, 3, 4 or 5 of the hydrogen atoms, is replaced with halogen atoms, in particular by fluorine or chlorine. Examples are 1- and 2-fluorocyclopropyl, 1,2-, 2,2- and 2,3-difluorocyclopropyl, 1,2,2-trifluorocyclopropyl, 2,2,3,3-tetrafluorocyclpropyl, 1- and 2- chlorocyclopropyl, 1,2-, 2,2- and 2,3-dichlorocyclopropyl, 1,2,2-trichlorocyclopropyl, 2,2,3,3-tetrachlorocyclopropyl, 1-, 2- and 3-fluorocyclopentyl, 1,2- , 2,2-, 2,3-, 3.3-, 3,4-, 2,5-difluorocyclopentyl, 1-, 2- and 3-chlorocyclopentyl, 1,2-, 2,2-, 2,3 -, 3,3-, 3,4-, 2,5-dichlorocyclopentyl and the like.
[088] The term "cycloalkoxy" refers to a cycloalkyl group as defined above, which is attached via an oxygen atom to the remainder of the molecule.
[089] The term "halocycloalkoxy" refers to a halocycloalkyl group, as defined above, that is attached via an oxygen atom to the remainder of the molecule.
[090] The term "cycloalkylthio" refers to a cycloalkyl group, as defined above, which is attached via a sulfur atom to the remainder of the molecule.
[091] The term "halocycloalkylthio" refers to a halocycloalkyl group, as defined above, which is attached via a sulfur atom to the remainder of the molecule.
[092] The term "cycloalkylalkyl" refers to a cycloalkyl group as defined above, which is attached through an alkyl group, such as a C1-C5 alkyl group or a C1-C4 alkyl group, in particular a methyl group (=cycloalkylmethyl), to the remainder of the molecule.
[093] The term "cycloalkenyl", as used herein, and in the cycloalkenyl portions of cycloalkenyloxy and cycloalkenylthio, in each case, means a monocyclic, non-aromatic radical, with a single unsaturation, usually containing from 3 to 10, for example, 3 or 4 or 5 to 10 carbon atoms, preferably 3 to 8 carbon atoms. Examples of cycloalkenyl groups include cyclopropenyl, cycloeptenyl or cyclooctenyl.
[094] The term "halocycloalkenyl", as used herein, and in the halocycloalkenyl portions of halocycloalkenyloxy and halocycloalkenylthio, in each case, means a non-aromatic monocyclic radical, with a single unsaturation, usually containing from 3 to 10, e.g., 3 or 4 or 5 to 10 carbon atoms, preferably 3 to 8 carbon atoms, wherein at least one, for example 1, 2, 3, 4 or 5 of the hydrogen atoms, is replaced with halogen, in particular by fluorine or chlorine. Examples are 3,3-difluoro-cyclo-prop-1-yl and 3,3-dichlorocyclopropen-1-yl.
[095] The term "cycloalkenyloxy" refers to a cycloalkenyl group, as defined above, which is attached via an oxygen atom to the remainder of the molecule.
[096] The term "halocycloalkenyloxy" refers to a halocycloalkenyl group, as defined above, which is attached via an oxygen atom to the remainder of the molecule.
[097] The term "cycloalkenylthio" refers to a cycloalkenyl group, as defined above, which is attached via a sulfur atom to the remainder of the molecule.
[098] The term "halocycloalkenylthio" refers to a halocycloalkenyl group, as defined above, which is attached via a sulfur atom to the remainder of the molecule.
[099] The term "cycloalkenylalkyl" refers to a cycloalkenyl group as defined above that is attached via an alkyl group such as a C1-C5 alkyl group or a C1-C4 alkyl group, in particular a methyl group (=cycloalkenylmethyl) to the remainder of the molecule.
[0100] The term "carbocycle" or "carbocyclyl" in general includes a monocyclic group with 3 to 12 members, preferably a non-aromatic monocyclic with 3 to 8 members or one with 5 to 8 members, more preferably, a 5- or 6-membered group comprising from 3 to 12, preferably from 3 to 8 or 5 to 8, more preferably from 5 or 6 carbon atoms. Preferably, the term "carbocycle" embraces the cycloalkyl and cycloalkenyl groups as defined above.
[0101] The term "heterocycloalkyl" in general includes monocyclic saturated non-aromatic heterocyclic radicals with 3 to 8 members, especially with 6 members. Non-aromatic heterocyclic radicals usually comprise 1, 2 or 3 heteroatoms selected from N, O and S as ring members, where S atoms as ring members can be present as S, SO or SO2.
[0102] The term "heterocycloalkenyl" in general includes heterocyclic radicals singly unsaturated monocyclic non-aromatic with 3 to 8 members, especially with 6 members. Non-aromatic heterocyclic radicals usually comprise 1, 2 or 3 heteroatoms selected from of N, O and S as ring members, wherein the S atoms as ring members can be present as S, SO or SO2.
[0103] The term "heterocycle" or "heterocyclyl" in general includes heterocyclic, non-aromatic monocyclic radicals with 3 to 12 members, preferably with 3 to 8 members or with 5 to 8 members, more preferably with 5 or 6 members, especially with 6 members. Non-aromatic heterocyclic radicals usually comprise 1, 2, 3, 4 or 5, preferably 1, 2 or 3 heteroatoms selected from N, O and S as ring members, where S atoms as ring members they can be present as S, SO or SO2. Examples of 5- or 6-membered heterocyclic radicals include saturated or unsaturated non-aromatic heterocyclic rings, such as oxiranyl, oxetanyl, tietanyl, tietanyl-S-oxide (S-oxothiyetanyl), tietanyl-S-dioxide (S-) rings. dioxothietanyl), pyrrolidinyl, pyrrolinyl, pyrazolinyl, tetrahydrofuranyl, dihydrofuranyl, 1,3-dioxolanyl, thiolanyl, S-oxothiolanyl, S-dioxothiolanyl, dihydrothienyl, S-oxodihydrothienyl, S-dioxodihydrothienino, thienoyl piperidinyl, oxazolinyl, oxazolinyl , pyranyl, dihydropyranyl, tetrahydropyranyl, 1,3- and 1,4-dioxanyl, thiopyranyl, S-oxothiopyranyl, S-dioxothiopyranyl, dihydrothiopyranyl, S-oxodihydrothiopyranyl, S-dioxodihydrothiopyranyl, tetrahydrothiopyranyl, S-oxothiopyranyl, S-dioxothiopyranyl, dihydrothiopyranyl, S-oxodihydrothiopyranyl, S-dioxodihydrothiopyranyl, tetrahydrothiopyranyl, S-oxothiopyranyl, S-pyranyl thiomorpholinyl, S-oxothiomorpholinyl, S-dioxothiomorpholinyl, thiazinyl and the like. Examples of heterocyclic ring also comprise 1 or 2 carbonyl groups as ring members comprising pyrrolidin-2-onyl, pyrrolidin-2,5-dionyl, imidazolidin-2-onyl, oxazolidin-2-onyl, thiazolidin-2-onyl and the like.
[0104] The term "aryl" includes mono-, bi- or tricyclic aromatic radicals normally containing from 6 to 14, preferably 6, 10 or 14 carbon atoms. Examples of aryl groups include phenyl, naphthyl and anthracenyl. Phenyl is preferably as an aryl group.
[0105] The term "heteroaryl" includes 5- or 6-membered monocyclic heteroaromatic radicals comprising as ring members 1, 2, 3 or 4 heteroatoms selected from N, O and S. Examples of 5- or 6-membered heteroaromatic radicals 6-membered include pyridyl, i.e., 2-, 3-, or 4-pyridyl, pyrimidinyl, i.e., 2-, 4- or 5-pyrimidinyl, pyrazinyl, pyridazinyl, i.e., 3- or 4- pyridazinyl, thienyl, i.e., 2- or 3-thienyl, furyl, i.e., 2- or 3-furyl, pyrrolyl, i.e., 2- or 3-pyrrolyl, oxazolyl, i.e., 2, 3 - or 5-oxazolyl, isoxazolyl, i.e., 3-, 4- or 5-isoxazolyl, thiazolyl, i.e., 2-, 3- or 5-thiazolyl, isothiazolyl, i.e., 3-, 4- or 5 -isothiazolyl, pyrazolyl, i.e., to 1-, 3-, 4- or 5-pyrazolyl, i.e., to 1-, 2-, 4- or 5-imidazolyl, oxadiazolyl, for example, to 2- or 5- [1,3,4]oxadiazolyl, 4- or 5-(1,2,3-oxadiazol)yl, 3- or 5-(1,2,4-oxadiazol)yl, 2- or 5-(1,3 ,4-thiadiazolyl, thiadiazolyl, e.g. 2- or 5-(1,3,4-thiadiazole) yl, 4- or 5-(1,2,3-thiadiazol)yl, 3- or 5-(1,2,4-thiadiazol)yl, triazolyl, e.g., 1H-, 2H- or 3H-1,2 ,3-triazol-4-yl, 2H-triazol-3-yl, 1H-, 2H-, or 4H-1,2,4-triazolyl and tetrazolyl, i.e., 1H- or 2H-tetrazolyl. The term "heteroaryl" also includes 8 to 10 membered heteroaromatic bicyclic radicals comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S, wherein a 5 or 6 membered heteroaromatic ring is fused with a phenyl ring or a 5- or 6-membered heteroaromatic radical. Examples of a 5- or 6-membered heteroaromatic ring fused to a phenyl ring or a 5- or 6-membered heteroaromatic radical include benzofuranyl, benzothienyl, indolyl, indazolyl, benzimidazolyl, benzoxathiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzoxazinyl, quinolinyl, isoquinolinyl purinyl, 1,8-naphthyridyl, pteridyl, pyrido[3,2-d]pyrimidyl or pyridoimidazolyl and the like. These fused hetaryl radicals may be attached to the remainder of the molecule via any ring atom of the 5- or 6-membered heteroaromatic ring or via a carbon atom of the fused phenyl moiety.
[0106] The terms "heterocyclyloxy", "hetaryloxy", "aryloxy" and "phenoxy" refer to heterocyclyl, hetaryl and aryl, as defined above, and phenyl, which are linked via an oxygen atom to the remainder of the molecule.
[0107] The terms "heterocyclylsulfonyl", "hetarylsulfonyl", "arylsulfonyl" and "phenylsulfonyl" refer to heterocyclyl, hetaryl and aryl as defined above, and phenyl, respectively, which are linked via a sulfur atom of a group sulfonyl to the rest of the molecule.
[0108] The terms "heterocyclylcarbonyl", "hetarylcarbonyl", "arylcarbonyl" and "phenylcarbonyl" refer to heterocyclyl, hetaryl and aryl, as defined above, and phenyl, respectively, which are linked via a carbon atom of a carbonyl group (C=O) to the rest of the molecule.
[0109] The terms "heterocyclylalkyl" and "hetarylalkyl" refer to heterocyclyl or hetaryl, respectively, as defined above, which are linked via a C1-C5 alkyl group or a C1-C4 alkyl group, in particular a group methyl (= heterocyclylmethyl or hetarylmethyl, respectively), to the remainder of the molecule.
[0110] The terms "arylalkyl" and "phenylalkyl" refer to aryl as defined above and phenyl, respectively, which are linked via a C1-C5 alkyl group or a C1-C4 alkyl group, in particular, a methyl group (= arylmethyl or phenylmethyl), to the remainder of the molecule, examples including benzyl, 1-phenylethyl, 2-phenylethyl and the like.
[0111] The term "arylalkoxy" and "benzyloxy" refer to arylalkyl, as defined above, and phenyl-C1 alkyl, respectively, which are attached via an oxygen atom to the remainder of the molecule.
[0112] The terms "alkylene", "cycloalkylene", "heterocycloalkylene", "alkenylene", "cycloalkenylene", "heterocycloalkenylene" and "alkynylene" refer to alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl and alkynyl, as defined above, respectively, which are linked to the remainder of the molecule by means of two atoms, preferably by means of two carbon atoms, of the respective group, so that they represent a linker between two portions of the molecule.
[0113] The term "cyclic moiety" may refer to any cyclic groups, which are present in the compounds of the present invention, and which are defined above, for example, to cycloalkyl, cycloalkenyl, carbocycle, heterocycloalkyl, heterocycloalkenyl, heterocycle, aryl, hetaryl and the like.
[0114] The observations made below regarding the preferred embodiments of the variables of the compounds of Formulas I, II, III, IV, V, Va, Vb, Vc, VI, VII and VIII and their subvariants are valid by themselves, a combination of each other, as well as with respect to the processes and compounds, according to the present invention.
[0115] As indicated above, the present invention relates to an embodiment of a process for the preparation of a pyrazole compound of Formula V which comprises the step of cyclizing an α,β-unsaturated carbonyl compound substituted with hydrazone of Formula IV by reaction with a reagent comprising an R6 group. Preferred embodiments of the present invention relate to the preparation of compounds of Formula IV and other conversions of specific compounds that are included in generic Formula V, in particular, Va, Vb and Vc.
[0116] In view of the fact that the compounds of Formula V of the present invention can be obtained according to the sequence comprising the steps (a) I-> II, (b) II + III -> IV and (c) ) IV -> V, as described above and below, and in view of the fact that compounds of Formula V, if provided, for example, as compounds of Formula Va and Vb, can still be converted according to the sequence comprising the steps (d) Va or Vb->Vc, (e) Vc->VI and (f) VI + VII->VIII, as described above and below, the substituents which preferably are for the compounds of Formula V, will also preferably be for its precursors I, II, III and IV, provided that the substituents are present and the same substituents will also be preferably for the compounds, obtainable from the compounds of Formula Va, Vb and Vc, that is, the compounds of Formula VI and VIII, provided the substituents are present.
[0117] The R 1 substituent is present at the 4-position of the pyrazole ring of the Formula V compounds. The R 1 substituent is also present in the precursors III and IV of the Formula V compounds.
[0118] In a preferred embodiment of the present invention, R1 is: - H, halogen, CN, NO2, C1-C10 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1, 2 or 3 identical or different Rx substituents, - C(Y)ORc, S(O)mRd, S(O)mY1Rd, C3-C12 cycloalkyl, aryl or hetaryl, where the cyclic moieties may be unsubstituted or may be substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the radicals Ry and Rx; - wherein Rc is H, C1-C4 alkyl or aryl C1-C4 alkyl, or wherein Rc together with the C(Y)O group forms a [C(Y)O]-NH4+ salt, [C(Y) )O]-Ma+ or [C(Y)O]-%Mea2+, where Ma is an alkali metal and Mea is an alkaline earth metal; - where Rd is C1-C4 alkyl, C3-C6 cycloalkyl, aryl or hetaryl; - where Y is the O; and - wherein Y1 is O or NR1a, wherein R1a is C1-C4 alkyl, C3-C6 cycloalkyl, aryl or hetaryl.
[0119] In a more preferred embodiment of the present invention, R1 is CN or C(Y)ORc, wherein Y is O and Rc is C1-C4 alkyl or benzyl, preferably ethyl or tert-butyl .
[0120] Compounds of Formula V, wherein R1 is C(Y)ORc with Y being the O and Rc being C1-C4 alkyl or aryl C1-C4 alkyl, or wherein Rc together with the C(group) O)O forms a [C(O)O]-NR4+, [C(O)O]-Ma+ or [C(O)O]-%Ma2+ salt, where Ma is an alkali metal and Mea is an alkali metal earthy; and wherein the R substituents on the nitrogen atom, independently of one another, are selected from H, C1-C10 alkyl, phenyl and phenyl-C1-C4 alkyl, are referred to as the compounds of Formula Va.

[0121] The compounds of Formula V, which correspond to the compounds of Formula Va, are preferably in accordance with the present invention. Compounds of Formula Va can be directly obtained from compounds of Formula IV according to the process of the present invention and can easily be converted to compounds of Formula Vc for the preparation of compounds of Formula VIII by means of activated compounds of Formula SAW.
[0122] In a particularly preferred embodiment of the present invention, the compound of Formula V is a compound of Formula Va, wherein Rc is C1-C4 alkyl or aryl C1-C4 alkyl, preferably C1-C4 alkyl or benzyl.
[0123] Compounds of Formula V, wherein R1 is the CN, are referred to as compounds of Formula Vb.

[0124] Compounds of Formula V, which correspond to compounds of Formula Vb, are preferably in accordance with the present invention. Compounds of Formula Vb can be directly obtained from compounds of Formula IV according to the process of the present invention and can easily be converted to compounds of Formula Vc for the preparation of compounds of Formula VIII by means of activated compounds of Formula SAW.
[0125] The compounds of Formula V, wherein R1 is C(Y)ORc with Y being the O and Rc being the H, are referred to as the compounds of Formula Vc.

[0126] Compounds of Formula V, which correspond to compounds of Formula Vc, are preferably in accordance with the present invention. In certain situations, compounds of Formula Vc can be directly obtained from compounds of Formula IV, according to the process of the present invention. However, it may be preferable to carry out the cyclization of the compounds of Formula IV with the carboxylic acid group masked as an ester or a nitrile group. Therefore, compounds of Formula Vc can also be obtained from compounds of Formula Va or Vb, as described above. The Formula Vc compounds therefore represent the versatile reaction tools for the preparation of Formula VIII 4-pyrazole N-(het)arylamide compounds, as they can easily be activated for a further amidation reaction to provide the 4-pyrazole N-(het)arylamide compounds of Formula VIII.
[0127] The R2 substituent is present at the 5-position of the pyrazole ring of the compounds of Formulas V, Va, Vb, Vc, VI and VIII. Furthermore, the R2 substituent is present in precursors III and IV of the compounds of Formula V.
[0128] In a preferred embodiment of the present invention, R2 is: - C1-C10 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1, 2 or 3 identical or different Rx substituents , - C3-C12 cycloalkyl, aryl or hetaryl, in which the last three mentioned radicals can be unsubstituted or can be substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the radicals Ry and Rx.
[0129] In a more preferred embodiment of the present invention, R2 is C1-C4 alkyl, which may be unsubstituted, or may be partially or fully halogenated.
[0130] It is even more preferred that R2 is CH3, CH2CH3 or fluoromethyl, and particularly preferably that R2 is CH3, CF2H or CF3.
[0131] The R3 substituent is present at the 3-position of the pyrazole ring of the compounds of Formulas V, Va, Vb, Vc, VI and VIII. Furthermore, the R3 substituent is present in precursors III and IV of the compounds of Formula V.
[0132] In a preferred embodiment of the present invention, R2 is: - the H, C1-C10 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1, 2 or 3 substituents Rx, identical or different, - C3-C12 cycloalkyl, aryl or hetaryl, wherein the cyclic moieties can be unsubstituted or can be substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the radicals Ry and Rx. -
[0133] In a most preferred embodiment of the present invention, R3 is the H.
[0134] As indicated above, the process according to the present invention is especially advantageous for the regioselective preparation of N-substituted pyrazole compounds, which are substituted with 3 or 5 or substituted with different substituents in position 3 and 5 Therefore, compounds of Formula V, wherein R3 and R2 are different from each other are particularly preferred. It is particularly preferably that one of R3 and R2 is H and the other is different from H. Alternatively, it may preferably be that R3 and R2 are both different from H and different from each other.
[0135] The compounds of Formula V, wherein R3 is different from H and wherein R2 is H, are to be understood as the 3-substituted N-substituted pyrazole compounds and are referred to as the compounds of Formula V.3- R3subst5-H, where R3subst refers to a defined substituent for R3, which is other than H.
[0136] The compounds of Formula V, wherein R3 is H and wherein R2 is other than H, are to be understood as the N-substituted pyrazole compounds, substituted with 5 and are referred to as the compounds of Formula V.3 -H.5-R2subst, where R2subst refers to a defined substituent for R2, which is other than H.
[0137] The compounds of Formula V, wherein R3 and R2 are different from H and different from each other, are to be understood as the N-substituted pyrazole compounds, substituted with 3 and 5, wherein the substituents in position 3 and 5 are different from each other. Such compounds are referred to as the compounds of Formula V.3-R3subst.5-R2subst, wherein R3subst refers to a defined substituent for R3, which is other than H, and wherein R2subst refers to a defined substituent for R2, which is different from H, with the proviso that R3subst and R2subst are different from each other. The compounds are represented below.

[0138] The meanings for R2 and R3, ie that one of R3 and R2 is H and the other is different from H, or that R3 and R2 are both different from H and different from each other, also preferably are for precursors III and IV as well as compounds of Formulas Va, Vb, Vc, VI and VIII.
Compounds of Formula V.3-H.5-R2subst and analogously substituted compounds of Formulas III, IV, Va, Vb, Vc, VI and VIII are particularly preferred in accordance with the present invention.
[0140] The substituents R4 and R5 are present in the compounds of Formulas I, II, IV, V, Va, Vb, Vc, VI and VIII.
[0141] In a preferred embodiment of the present invention, - R4 is selected from C1-C10 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1, 2 or 3 identical Rx substituents or different; and - C3-C10 cycloalkyl, which may be unsubstituted or may be substituted with 1, 2, 3, 4, or 5 identical or different Ry substituents; and - R5 is selected from C1-C10 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1, 1, 2 or 3 identical or different Rx substituents; and - C3-C10 cycloalkyl, which may be unsubstituted or may be substituted with 1, 2, 3, 4 or 5 identical or different Ry substituents.
[0142] In a more preferred embodiment of the present embodiment, - R4 is selected from C1-C4 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1 or 2 identical or Rx substituents different, where Rx is selected from CN and C(O)NH2, and - C3-C6 cycloalkyl, which may be unsubstituted or may be substituted with 1, 2 or 3 identical or different Ry substituents, where Ry is selected from halogen, CN and C(O)NH2; and - R5 is selected from C1-C4 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1 or 2 identical or different Rx substituents, wherein Rx is selected from CN and C(O)NH2, e - C3-C6 cycloalkyl, which may be unsubstituted or may be substituted with 1, 2 or 3 Ry or identical or different substituents, where Ry is selected from halogen, CN and C(O )NH2.
[0143] In an even more preferred embodiment of the present embodiment, - R4 is selected from C1-C4 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1 or 2 identical Rx substituents or different, where Rx is selected from CN and C(O)NH2, and - C3-C6 cycloalkyl, which may be unsubstituted or may be substituted with 1, 2 or 3 identical or different Ry substituents, where Ry is selected from halogen, CN and C(O)NH2; and - R5 is selected from C1-C2 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1 or 2 identical or different Rx substituents, wherein Rx is selected from CN and C (O)NH2, e - C3-C4 cycloalkyl, which may be unsubstituted or may be substituted with 1, 2 or 3 Ry or identical or different substituents, where Ry is selected from halogen, CN and C(O) NH2.
[0144] It is particularly preferably according to this embodiment of the present invention that R4 and R5 are different from each other. For example, R5 may be C1-C2 alkyl, which is unsubstituted, or C3C4 cycloalkyl, which is unsubstituted, while R4 may be C1-C4 alkyl, which may be unsubstituted, or partially or fully halogenated, or substituted with 1 or 2 identical or different Rx substituents selected from CN and C(O)NH2, or it can be C3-C6 cycloalkyl which preferably can be substituted with 1, 2 or 3 identical or different Ry substituents selected from of halogen, CN and C(O)NH2.
[0145] More preferably, R5 is CH3, while R4 is C1-C4 alkyl, C1-C2 haloalkyl or C3 cycloalkyl, wherein the cycloalkyl group is preferably substituted with a substituent selected from CN and C (O)NH2. Suitable combinations of R5 and R4, for example, may be CH3/i-Pr or CH3/1-CN-cC3H4.
[0146] In another preferred embodiment of the present invention, - R4 and R5 together with the carbon atom to which they are attached form a non-aromatic carbocycle with 3 to 12 members, which can be partially or fully substituted with Rj.
[0147] In a more preferred embodiment of the present embodiment, - R4 and R5 together with the carbon atom to which they are attached form a 3- to 12-membered non-aromatic saturated carbocycle, which may be partially or fully substituted with Rj , where Rj is selected from halogen, CN and C(O)NH2.
[0148] In an even more preferred embodiment of the present embodiment, - R4 and R5, together with the carbon atom to which they are attached, form a 3 to 6-membered non-aromatic saturated carbocycle, which may be partially or fully substituted with Rj, where Rj is selected from halogen, CN and C(O)NH2.
[0149] It is particularly preferably, according to this embodiment of the present invention, that R4 and R5 together with the carbon atom to which they are attached form a 6-membered carbocycle which is partially or fully halogenated, preferably fluorinated . In this way, R4 and R5 together can represent, for example, -CH2CH2CF2CH2CH2-.
[0150] The R6 substituent is present in the compounds of Formulas V, Va, Vb, Vc, VI and VIII and in the reagent, with which the compound of Formula IV is reacted to provide the compound of Formula V.
[0151] In a preferred embodiment of the present invention, R6 is selected from H, CN and C1-C2 fluoroalkyl. More preferably, R6 is selected from H, CN, CHF2 and CF3 and most preferably R6 is H.
[0152] The compounds of Formula V, wherein R6 is the H may be referred to as the compounds of Formula V.R6-H.
Compounds of Formula V.R6-H and similarly substituted compounds of Formulas Va, Vb, Vc, VI and VIII are particularly preferred in accordance with the present invention.
[0154] The compounds of Formula V.3-H.5-R2subst, wherein R6 is the H, that is, the compounds of Formula V.3-H.5-R2subst.R6-H and the compounds substituted in a manner analogs of Formulas III, IV, Va, Vb, Vc, VI and VIII are particularly preferred in accordance with the present invention.
[0155] As indicated above, a center of chirality can be formed after the formation of the compounds of Formula V by reacting a compound of Formula IV with a reagent comprising an R6 group, if the R4 and R5 substituents of the compound de Formula IV and R6 are different from each other. If two or more of the three substituents R4, R5 and R6 are identical, no center of chirality will be formed after formation of the compounds of Formula V. It is particularly preferred in accordance with the present invention that R4, R5 and R6 are different between them, so that a center of chirality is formed. If a center of chirality is formed, it is preferably that the two possible configurations of the center of chirality are formed in equal amounts. Therefore, the formation of the compounds of Formula V according to the present invention is normally not stereoselective, but a mixture, preferably a racemic mixture, of the two possible stereoisomers is obtained. If a center of chirality is present in the -CR4R5R6 group of the compounds of Formula V, the generic Formula V, therefore, is preferably intended to encompass a mixture of the two possible stereoisomers. If there are no more chirality centers in the compound, the stereoisomers are enantiomers, otherwise the stereoisomers can be diastereoisomers. The same considerations also apply to the generic Formulas Va, Vb, Vc, VI and VIII.
[0156] With respect to the reagent comprising the R6 group, which is reacted with the compounds of Formula IV to provide the compounds of Formula V, the following is noted.
[0157] For R6 being the H, it is preferably that the reactant is present in the form of "R6 reactant", and transfers the H as a hydride. In certain situations, it may also be preferable for the reagent to transfer the H as a hydrogen radical.
[0158] In a preferred embodiment of the present invention, the reagent comprising the H as the R6 group is a reducing agent. Preferably, the reducing agents are selected from: (ia) ionic hydride donors selected from the group consisting of complex boron aluminum hydrides, (ib) nonionic hydride donors selected from the group consisting of in dihydrogen, which is especially used in combination with a metal catalyst, Hantzsch ester, 1,4-dihydrobenzol, isopropanol, formic acid and ammonium formate; and (ic) electron donors, which are used in combination with protons, in which electrons are donated by a cathode or a metal selected from Li, Na, K, Mg, Zn, Fe and Al.
[0159] Ionic hydride donors are described below and are particularly preferred in accordance with the present invention.
[0160] Although the term "ionic" indicates that "ionic hydride donors" have an ionic structure, ionic hydride donors mainly belong to the group of reagents, which comprise the R6, that is, the H, covalently linked and, therefore, they can be referred to as "H-reagent", which can react with the compounds of Formula IV. However, an ionic structure, however, is present in ionic hydride donors since the reagent, which comprises the covalently bonded H, is itself ionic, preferably anionic, that is, in the form "[H reagent] ", so that the reactant is normally supplied in the form of a "Ct+[H reagent]-" salt, where Ct+ represents a cation, e.g., an alkali metal cation, and "[H-reagent]-" is as defined above. Preferably, the ionic hydride donor is a negatively charged hydride complex of a metal which is provided in the form of a salt and is capable of transferring H as a hydride.
[0161] In a special preference embodiment of the present invention, the ionic hydride donor is selected from the group consisting of complex hydrides of boron and aluminum.
[0162] The term "complex boron or aluminum hydride" refers to the complex hydride of boron or aluminum. In this way, R6 being the H can be covalently bonded to a boron or aluminum atom to provide a hydride complex, which is capable of transferring the H as a hydride, as indicated above. Preferably, the boron or aluminum complex is negatively charged due to the presence of four substituents, one of which is H as the R6 group, which can be transferred in the form of a hydride, and the remaining three substituents, independently between themselves, for example, they can be selected from the group consisting of H, C1-C4 alkyl, C1-C4 alkoxy and CN. In this way, the complex can be described by the Formula "[H reagent]-" defined above. Typically, the anhydrous complex of boron or aluminum hydride is combined with a cation in the form of a salt, for example, in accordance with the Formula "Ct+[H reagent]-" mentioned above. The Ct+ cation is usually an alkali metal ion which is preferably Na+ or Li+.
[0163] Preferred complex hydrides of boron and aluminum include Na+[BH4]-, Na+[B(CN)H3]-, Na+[BH(OAc)3]-, Li+[AlH4]-, Li+[BH4 ]-, Li+[BHEt3]-, Li+[BH(sec-Bu)3]- and the like. Usually preferably these are complex aluminum hydrides, if a high reactivity of the reagent comprising the R6 group is desired. Complex boron hydrides are typically the lightest reducing agents. For purposes of the present invention, complex boron hydrides are usually preferred. More preferably, the reagent comprising R6 is Na+[BH4]- or Na+[BCNH3]-, particularly preferably Na+[B(CN)H3]-. The reagent Na+[B(CN)H3]- has the following structure.

[0164] Typically, Na+[B(CN)H3]- is also referred to as NaB(CN)H3 or NaBH3CN. Similarly, also the other complex boron aluminum hydrides listed above are often referred to by a Molecular Formula without indicating charges.
[0165] The structures of other complex aluminum and boron hydrides, including those listed above, are analogous.
[0166] The following are described the non-ionic hydride donors.
[0167] The term "nonionic hydride donor" refers to reagents comprising an R6 group which is H, which are nonionic and normally belong to the group of reagents which comprise R6, i.e. H, covalently bonded . Preferably, the non-ionic hydride donor is an uncharged hydrogen source, which is capable of transferring H in the form of a hydride, and usually also transfers a proton, so that a dihydrogen molecule is terminated. If the reactants transfer H in the form of a hydride, they can again be considered as "H-reagent" as described above.
[0168] As used herein, the term "nonionic hydride donor" also encompasses dihydrogen since the result of a hydrogenation reaction with dihydrogen mainly can also be observed in the transfer of a hydride and a proton. However, such hydrogenation can naturally also occur as such, so that two uncharged hydrogen atoms, ie the hydrogen radicals, are transferred.
[0169] In a particularly preferred embodiment of the present invention, the reagent comprising the R6 group is a nonionic hydrogen donor, which is selected from the group consisting of Hantzsch ester, 1,4-dihydrobenzol, isopropanol, formic acid, ammonium formate and dihydrogen.
[0170] Hantzsch ester, 1,4-dihydrobenzol, isopropanol, formic acid and ammonium formate are also known in the prior art as "transfer hydrogenation reagents". They can be considered as hydrogen sources as they can transfer a hydride ion and a proton. Reactions with these transfer hydrogenation reagents can usually be carried out without metal, that is, in the absence of a metal catalyst.
[0171] The reaction with dihydrogen (H2) as a reducing agent is preferably carried out in combination with a metal catalyst. A person skilled in the art knows the suitable metal catalysts to be used in combination with dihydrogen. Examples of suitable metal catalysts are given below.
[0172] The reduction cyclization is described below, which is performed with protons in combination with electrons provided by an electrode or by a metal.
[0173] Protons are preferably provided by protic solvents, preferably water or an alcohol such as methanol, ethanol or isopropanol, and electrons are generated from an electrode (cathode) or a suitable metal, preferably a metal selected from Li, Na, K, Mg, Fe and Al.
[0174] For R6 being different from H, the reactant may be present in a form, where R6 is covalently bonded, that is, in the form of "R6 reactant", or in the form of a salt with R6 representing the anion, this is in the form of "[reagent]+[R6]-".
[0175] In a preferred embodiment of the present invention, the reagent comprising the R6 group other than H is an organometallic reagent, wherein R6 is selected from C1-C6 fluoroalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl-C1-C2 alkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenyl-C1-C2 alkyl, heterocyclyl, heterocyclyl-C1-C2 alkyl, aryl, aryl-C1 alkyl -C2, hetaryl, hetaryl-C1-C2 alkyl, wherein the carbon chains or cyclic moieties may be unsubstituted, partially or fully substituted with identical or different Rx substituents. Preferably, the reagent comprising the R6 group is an organometallic reagent, wherein R6 is selected from C1-C4 fluoroalkyl, C1-C4 alkyl, aryl, arylmethyl and allyl, and wherein R6 is particularly preferably selected from C1-C2 fluoroalkyl, in particular from CH2F and CF3.
[0176] Preferably, the organometallic reagent comprises a metal M selected from Li, Mg, Cu, Zn, Si, Mn or In. Depending on the metal, the organometallic reagent can be considered as "R6 reagent" (for example , M-R6) or "[reagent]+[R6]-" (eg [M]+[R6]-), but should be considered as "R6 reagent" since the metals listed above are known to form the covalent bonds rather than ionic bonds with the organic groups as listed above for R6.
[0177] Preferably organometallic reagents according to the present invention include Grignard reagents, cuprate reagents, allyl silanes (Hosomi-Sakurai reagents) and fluoroalkyl silanes (eg Ruppert's reagent).
[0178] Particularly preferably, the organometallic reagent is Ruppert's reagent, that is, the trimethyl(trifluoromethyl)silane, which transfers the CF3 as an R6 group.
[0179] In another preferred embodiment of the present invention, the reagent comprising the group R6 being other than H is a nucleophilic reagent of Formula H-R6, Ma+R6- or %Mea2+R6', wherein Ma is a metal alkaline and Mae is an alkaline earth metal, and wherein R6 is selected from CN, ORa, SRa, NReRf, and groups of General Formula (i)
- where Ra, Re, Rf, Rr, Rs and Rt are as defined above.
[0180] The wavy line in the groups of general Formula (i) indicated the position, where group (i) may be linked to H according to Formula H-R6, or may have been deprotonated to give a salt of Formula Ma+R6- or %Mea2+R6-. If group (i) is present in deprotonated, ie, anionic form, the negative charge can be delocalized onto the 1,3-di(thio)carbonyl system. However, it is observed that the carbon atom between the two (thio)carbonyl groups, however, will be in the nucleophilic position of the group (i). Preferably groups (i) are 1,3-dicarbonyl compounds, which have been deprotonated at the 2-position with a suitable base and therefore are present in anionic form in combination with a cation, which originates from the base. The reagent comprising group (i) as group R6 can therefore preferably be represented by the Formula Ma+R6- or %Mea2+R6-, which can be considered to be included in the above Formula "[reagent]+ [R6]-" and where Ma, for example, can be Li, K or Na, and Mea, for example, can be Mg or Ca. It is observed that if the reagent comprising group (i) as group R6 which is included in Formula H-R6, can be considered as an "reagent of R6" described above with the "reagent" being H.
[0181] Preferred ORa groups include C1-C4 alkoxy and C3-C6 cycloalkoxy.
[0182] SRa groups preferably include C1-C4 alkylthio and C3-C6 cycloalkylthio.
Preferred NReRf groups include C1-C4 alkylamino, C1-C4 dialkylamino, where the alkyl chains may be of identical or different length, morpholine, piperazine and N-methylpiperazine.
[0184] For the R6 group being ORa, SRa or NReRf, the reagent comprising the R6 group may be represented by Formula H-R6, which may be considered to be included in the above Formula "R6 reagent", or by either of Formulas Ma+R6- and %Mea2+R6-, which can be considered to be included in the above Formula "[reagent]+[R6]-", and where Ma, for example, can be Li, K or Na, and Mea, for example, may be Mg or Ca. For the reagent comprising ORa or SRa as group R6, it may preferably be that the reagent is present in the form of Ma+R6- or %Mea2+R6-. For the reagent comprising the NReRf as the R6 group, it may preferably be that the reagent is present in the form of H-R6 as the H-NReRf also has a nucleophilic reactivity if used in the protonated form.
[0185] For the group R6 being the CN, similar considerations apply. Therefore, the reagent comprising CN as the R6 group can be represented by Formula H-R6, which can be considered to be included in the above Formula "R6 reagent", or by any one of Formulas Ma+R6- and %Mea2+ R6-, which can be considered to be included in the above Formula "[reagent]+[R6]-", and where Ma, for example, can be Li, K or Na, and Mea, for example, can be Mg or Ca. If R6 is CN, the reagent comprising the R6 group is preferably HCN, NaCN or KCN.
[0186] It is observed that, particularly preferably, is that the reagent is a nucleophilic reagent comprising the group R6 where R6 is the CN. NaCN is a reagent, particularly preferably comprising an R6 group.
[0187] The following embodiments in relation to the reagent comprising an R6 group are preferably in accordance with the present invention.
[0188] In a preferred embodiment, the R6 group of the reagent comprising the R6 group is H, and the reagent comprising the R6 group is selected from: (ia) ionic hydride donors selected from the group that consists of complex aluminum borohydrides, or (ib) nonionic hydride donors selected from the group consisting of dihydrogen which is preferably used in combination with a metal catalyst, Hantzsch ester, 1,4- dihydrobenzol, isopropanol, formic acid and ammonium formate.
[0189] In another preferred embodiment, the R6 group of the reagent comprising the R6 group is H, and the reagent comprising the R6 group is selected from: (ia) ionic hydride donors selected from the group that consists of complex aluminum boron hydrides, or (ib) dihydrogen, which is used in combination with a metal catalyst.
[0190] With respect to option (a), the following embodiments are preferably.
[0191] In a preferred embodiment, the R6 group of the reagent comprising the R6 group is H, and the reagent comprising the R6 group is an alkaline salt of a negatively charged boron or aluminum complex, wherein boron or aluminum is substituted with four substituents, at least one of which is H, and the remaining three substituents are independently selected from the group consisting of H, C1-C4 alkyl, C1C4 alkoxy, and CN.
[0192] In a more preferred embodiment, the R6 group of the reagent comprising the R6 group is H and the reagent comprising the R6 group is a sodium salt of a negatively charged boron complex, in which boron is substituted with four substituents, of which at least one is H, and the remaining three substituents are independently selected from the group consisting of H, C1-C4 alkyl, C1-C4 alkoxy and CN.
[0193] In a particularly preferred embodiment, the R6 group of the reagent comprising the R6 group is H, and the reagent comprising the R6 group is Na+[B(CN)H3]-.
[0194] With respect to option (b), the following embodiments are preferably.
[0195] In a preferred embodiment, the R6 group of the reagent comprising the R6 group is H, and the reagent comprising the R6 group is dihydrogen (H2), which is used in combination with a metal catalyst.
[0196] In a more preferred embodiment, the R6 group of the reagent comprising the R6 group is H, and the reagent comprising the R6 group is dihydrogen, which is used in combination with a metal catalyst selected from group consisting of Rayne's nickel, Pd/C, Pt/C and PtO2.
[0197] In an even more preferred embodiment, the R6 group of the reagent comprising the R6 group is H, and the reagent comprising the R6 group is dihydrogen, which is used in combination with a selected metal catalyst a starting from the group consisting of Rayney nickel, Pd/C, Pt/C and PtO2, and in which the didrogen is applied with a pressure not exceeding 100 bar and preferably not exceeding 50 bar.
[0198] In an even more preferred embodiment, the R6 group of the reagent comprising the R6 group is H, and the reagent comprising the R6 group is dihydrogen, which is used in combination with a selected metal catalyst a starting from the group consisting of Rayney nickel, Pd/C, Pt/C and PtO2, and in combination with a catalytic amount of an acid, and wherein the dihydrogen is applied with a pressure not exceeding 100 bar and preferably , does not exceed 50 bar.
[0199] In an even more preferred embodiment, the R6 group of the reagent comprising the R6 group is H, and the reagent comprising the R6 group is dihydrogen, which is used in combination with a selected metal catalyst a from the group consisting of Rayney nickel, Pd/C, Pt/C and PtO2, and in combination with a catalytic amount of an acid, which is selected from aromatic sulfonic acids such as toluenesulfonic acid; alkylsulfonic acids, such as methylsulfonic acid; aromatic carboxylic acids such as benzoic acid; alkylcarboxylic acids such as acetic acid; haloalkylcarboxylic acids such as trifluoroacetic acid and mineral acids such as hydrogen chloride or sulfuric acid in methanol and in which the dihydrogen is applied at a pressure not exceeding 100 bar and preferably not exceeding 50 bar.
[0200] In an even more preferred embodiment, the R6 group of the reagent comprising the R6 group is H, and the reagent comprising the R6 group is dihydrogen, which is used in combination with a selected metal catalyst a from the group consisting of Rayney nickel, Pd/C, Pt/C and PtO2, and in combination with a catalytic amount of an acid, which is selected from HCl, H2SO4 and trifluoroacetic acid and to which dihydrogen is applied with a pressure not exceeding 100, preferably not exceeding 50 bar.
[0201] In summary, the reagent comprising the R6 group, which is reacted with the compounds of Formula IV to provide the compounds of Formula V, may be: - a reducing agent which, preferably, may be an ionic hydride donor and particularly preferably is Na+[B(CN)H3]-; or - an organometallic reagent which preferably can be a silane, such as an allyl silane or a fluoroalkyl silane and particularly preferably is Ruppert's reagent; or - a nucleophilic reagent which preferably can be selected from HCN, or a salt such as NaCN or KCN, and particularly preferably is NaCN.
[0202] In summary, the following combinations of substituents in the compounds of Formula V and their precursors or the reagents used in the process of the present invention are preferably the following. TABLE 1
[0203] The combination, where R1 is the H, R2 is the CH3, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 2
[0204] The combination where R1 is H, R2 is CH3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 3
[0205] The combination, where R1 is H, R2 is CH3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 4
[0206] The combination, where R1 is the H, R2 is the C3H5, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 5
[0207] The combination, where R1 is H, R2 is C3H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 6
[0208] The combination, where R1 is H, R2 is C3H5, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 7
[0209] The combination, where R1 is the H, R2 is the C6H5, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 8
[0210] The combination, where R1 is H, R2 is C6H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 9
[0211] The combination, where R1 is the H, R2 is the C6H5, R3 is the C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 10
[0212] The combination, where R1 is the H, R2 is the CF2H, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 11
[0213] The combination, where R1 is the H, R2 is the CF2H, R3 is the CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 12
[0214] The combination, where R1 is the H, R2 is the CF2H, R3 is the C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 13
[0215] The combination, where R1 is the H, R2 is the CF2H, R3 is the C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 14
[0216] The combination, where R1 is the H, R2 is the CF3, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 15
[0217] The combination, where R1 is the H, R2 is the CF3, R3 is the CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 16
[0218] The combination, where R1 is the H, R2 is the CF3, R3 is the C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 17
[0219] The combination, where R1 is H, R2 is CF3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 18
[0220] The combination, where R1 is F, R2 is CH3, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 19
[0221] The combination, where R1 is F, R2 is CH3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 20
[0222] The combination, where R1 is F, R2 is CH3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 21
[0223] The combination, where R1 is the F, R2 is the C3H5, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 22
[0224] The combination, where R1 is F, R2 is C3H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 23
[0225] The combination, where R1 is F, R2 is C3H5, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 24
[0226] The combination, where R1 is the F, R2 is the C6H5, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 25
[0227] The combination, where R1 is F, R2 is C6H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 26
[0228] The combination, where R1 is F, R2 is C6H5, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 27
[0229] The combination, where R1 is the F, R2 is the CF2H, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 28
[0230] The combination, where R1 is F, R2 is CF2H, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 29
[0231] The combination, where R1 is the F, R2 is the CF2H, R3 is the C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 30
[0232] The combination, where R1 is F, R2 is CF2H, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 31
[0233] The combination, where R1 is the F, R2 is the CF3, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 32
[0234] The combination, where R1 is F, R2 is CF3, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 33
[0235] The combination, where R1 is F, R2 is CF3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 34
[0236] The combination, where R1 is F, R2 is CF3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 35
[0237] The combination, where R1 is CH3, R2 is CH3, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 36
[0238] The combination, where R1 is CH3, R2 is CH3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 37
[0239] The combination, where R1 is CH3, R2 is CH3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 38
[0240] The combination, where R1 is CH3, R2 is C3H5, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 39
[0241] The combination, where R1 is CH3, R2 is C3H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 40
[0242] The combination, where R1 is CH3, R2 is C3H5, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 41
[0243] The combination, where R1 is CH3, R2 is C6H5, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 42
[0244] The combination, where R1 is CH3, R2 is C6H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 43
[0245] The combination, where R1 is CH3, R2 is C6H5, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 44
[0246] The combination, where R1 is CH3, R2 is CF2H, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 45
[0247] The combination, where R1 is CH3, R2 is CF2H, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 46
[0248] The combination, where R1 is CH3, R2 is CF2H, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 47
[0249] The combination, where R1 is CH3, R2 is CF2H, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 48
[0250] The combination, where R1 is CH3, R2 is CF3, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 49
[0251] The combination, where R1 is CH3, R2 is CF3, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 50
[0252] The combination, where R1 is CH3, R2 is CF3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 51
[0253] The combination, where R1 is CH3, R2 is CF3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 52
[0254] The combination, where R1 is C6H5, R2 is CH3, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 53
[0255] The combination, where R1 is C6H5, R2 is CH3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 54
[0256] The combination, where R1 is C6H5, R2 is CH3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 55
[0257] The combination, where R1 is C6H5, R2 is C3H5, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 56
[0258] The combination, where R1 is C6H5, R2 is C3H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 57
[0259] The combination, where R1 is C6H5, R2 is C3H5, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 58
[0260] The combination, where R1 is C6H5, R2 is C6H5, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 59
[0261] The combination, where R1 is C6H5, R2 is C6H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 60
[0262] The combination, where R1 is C6H5, R2 is C6H5, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 61
[0263] The combination, where R1 is C6H5, R2 is CF2H, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 62
[0264] The combination, where R1 is C6H5, R2 is CF2H, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 63
[0265] The combination, where R1 is C6H5, R2 is CF2H, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 64
[0266] The combination, where R1 is C6H5, R2 is CF2H, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 65
[0267] The combination, where R1 is C6H5, R2 is CF3, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 66
[0268] The combination, where R1 is C6H5, R2 is CF3, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 67
[0269] The combination, where R1 is C6H5, R2 is CF3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 68
[0270] The combination, where R1 is C6H5, R2 is CF3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 69
[0271] The combination, where R1 is C(O)OCH3, R2 is CH3, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A TABLE 70
[0272] The combination, where R1 is C(O)OCH3, R2 is CH3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 71
[0273] The combination, where R1 is the C(O)OCH3, R2 is the CH3, R3 is the C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 72
[0274] The combination, where R1 is C(O)OCH3, R2 is C3H5, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 73
[0275] The combination, where R1 is C(O)OCH3, R2 is C3H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 74
[0276] The combination, where R1 is C(O)OCH3, R2 is C3H5, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 75
[0277] The combination, where R1 is C(O)OCH3, R2 is C6H5, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 76
[0278] The combination, where R1 is C(O)OCH3, R2 is C6H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 77
[0279] The combination, where R1 is C(O)OCH3, R2 is C6H5, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 78
[0280] The combination, where R1 is C(O)OCH3, R2 is CF2H, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 79
[0281] The combination, where R1 is C(O)OCH3, R2 is CF2H, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 80
[0282] The combination, where R1 is C(O)OCH3, R2 is CF2H, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 81
[0283] The combination, where R1 is C(O)OCH3, R2 is CF2H, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 82
[0284] The combination, where R1 is C(O)OCH3, R2 is CF3, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A TABLE 83
[0285] The combination, where R1 is C(O)OCH3, R2 is CF3, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 84
[0286] The combination, where R1 is C(O)OCH3, R2 is CF3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 85
[0287] The combination, where R1 is C(O)OCH3, R2 is CF3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 86
[0288] The combination, where R1 is C(O)OCH2CH3, R2 is CH3, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 87
[0289] The combination, where R1 is C(O)OCH2CH3, R2 is CH3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 88
[0290] The combination, where R1 is C(O)OCH2CH3, R2 is CH3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 89
[0291] The combination, where R1 is C(O)OCH2CH3, R2 is C3H5, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 90
[0292] The combination, where R1 is C(O)OCH2CH3, R2 is C3H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 91
[0293] The combination, where R1 is C(O)OCH2CH3, R2 is C3H5, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 92
[0294] The combination, where R1 is the C(O)OCH2CH3, R2 is the C6H5, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 93
[0295] The combination, where R1 is C(O)OCH2CH3, R2 is C6H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 94
[0296] The combination, where R1 is C(O)OCH2CH3, R2 is C6H5, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 95
[0297] The combination, where R1 is the C(O)OCH2CH3, R2 is the CF2H, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 96
[0298] The combination, where R1 is C(O)OCH2CH3, R2 is CF2H, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 97
[0299] The combination, where R1 is C(O)OCH2CH3, R2 is CF2H, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 98
[0300] The combination, where R1 is the C(O)OCH2CH3, R2 is the CF2H, R3 is the C6H5 and the combination of R4 and R5, in each case, corresponds to a line in Table A. TABLE 99
[0301] The combination, where R1 is C(O)OCH2CH3, R2 is CF3, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 100
[0302] The combination, where R1 is C(O)OCH2CH3, R2 is CF3, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 101
[0303] The combination, where R1 is C(O)OCH2CH3, R2 is CF3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 102
[0304] The combination, where R1 is C(O)OCH2CH3, R2 is CF3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 103
[0305] The combination, where R1 is C(O)OC(CH3)3, R2 is CH3, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 104
[0306] The combination, where R1 is C(O)OC(CH3)3, R2 is CH3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 105
[0307] The combination, where R1 is C(O)OC(CH3)3, R2 is CH3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 106
[0308] The combination, where R1 is C(O)OC(CH3)3, R2 is C3H5, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 107
[0309] The combination, where R1 is C(O)OC(CH3)3, R2 is C3H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 108
[0310] The combination, where R1 is C(O)OC(CH3)3, R2 is C3H5, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 109
[0311] The combination, where R1 is the C(O)OC(CH3)3, R2 is the C6H5, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 110
[0312] The combination, where R1 is C(O)OC(CH3)3, R2 is C6H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 111
[0313] The combination, where R1 is C(O)OC(CH3)3, R2 is C6H5, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 112
[0314] The combination, where R1 is the C(O)OC(CH3)3, R2 is the CF2H, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 113
[0315] The combination, where R1 is C(O)OC(CH3)3, R2 is CF2H, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 114
[0316] The combination, where R1 is C(O)OC(CH3)3, R2 is CF2H, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 115
[0317] The combination, where R1 is C(O)OC(CH3)3, R2 is CF2H, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 116
[0318] The combination, where R1 is the C(O)OC(CH3)3, R2 is the CF3, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 117
[0319] The combination, where R1 is C(O)OC(CH3)3, R2 is CF3, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 118
[0320] The combination, where R1 is C(O)OC(CH3)3, R2 is CF3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 119
[0321] The combination, where R1 is the C(O)OC(CH3)3, R2 is the CF3, R3 is the C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 120
[0322] The combination, where R1 is C(O)OCH2C6H5, R2 is CH3, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 121
[0323] The combination, where R1 is C(O)OCH2C6H5, R2 is CH3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 122
[0324] The combination, where R1 is C(O)OCH2C6H5, R2 is CH3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 123
[0325] The combination, where R1 is C(O)OCH2C6H5, R2 is C3H5, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 124
[0326] The combination, where R1 is C(O)OCH2C6H5, R2 is C3H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 125
[0327] The combination, where R1 is C(O)OCH2C6H5, R2 is C3H5, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 126
[0328] The combination, where R1 is C(O)OCH2C6H5, R2 is C6H5, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 127
[0329] The combination, where R1 is C(O)OCH2C6H5, R2 is C6H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 128
[0330] The combination, where R1 is C(O)OCH2C6H5, R2 is C6H5, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 129
[0331] The combination, where R1 is the C(O)OCH2C6H5, R2 is the CF2H, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 130
[0332] The combination, where R1 is C(O)OCH2C6H5, R2 is CF2H, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 131
[0333] The combination, where R1 is C(O)OCH2C6H5, R2 is CF2H, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 132
[0334] The combination, where R1 is C(O)OCH2C6H5, R2 is CF2H, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 133
[0335] The combination, where R1 is C(O)OCH2C6H5, R2 is CF3, R3 is H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 134
[0336] The combination, where R1 is C(O)OCH2C6H5, R2 is CF3, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 135
[0337] The combination, where R1 is C(O)OCH2C6H5, R2 is CF3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 136
[0338] The combination, where R1 is C(O)OCH2C6H5, R2 is CF3, R3 is C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 137
[0339] The combination, where R1 is the CN, R2 is the CH3, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 138
[0340] The combination, where R1 is CN, R2 is CH3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 139
[0341] The combination, where R1 is the CN, R2 is the CH3, R3 is the C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 140
[0342] The combination, where R1 is the CN, R2 is the C3H5, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 141
[0343] The combination, where R1 is the CN, R2 is the C3H5, R3 is the CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 142
[0344] The combination, where R1 is the CN, R2 is the C3H5, R3 is the C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 143
[0345] The combination, where R1 is the CN, R2 is the C6H5, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 144
[0346] The combination, where R1 is CN, R2 is C6H5, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 145
[0347] The combination, where R1 is the CN, R2 is the C6H5, R3 is the C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 146
[0348] The combination, where R1 is the CN, R2 is the CF2H, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 147
[0349] The combination, where R1 is CN, R2 is CF2H, R3 is CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 148
[0350] The combination, where R1 is CN, R2 is CF2H, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 149
[0351] The combination, where R1 is the CN, R2 is the CF2H, R3 is the C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 150
[0352] The combination, where R1 is the CN, R2 is the CF3, R3 is the H and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 151
[0353] The combination, where R1 is the CN, R2 is the CF3, R3 is the CH3 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 152
[0354] The combination, where R1 is CN, R2 is CF3, R3 is C3H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE 153
[0355] The combination, where R1 is the CN, R2 is the CF3, R3 is the C6H5 and the combination of R4 and R5, in each case, corresponds to a row in Table A. TABLE A




[0356] In a preferred embodiment of the present invention, the compounds of Formula V are the compounds, wherein R1, R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with the Table A, entries A-1 through A-159, and where R6 is the H.
[0357] In another preferred embodiment of the present invention, the compounds of Formula V are the compounds, wherein R1, R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with the Table A, entries A-1 through A-159, and where R6 is the CN.
[0358] In yet another preferred embodiment of the present invention, the compounds of Formula V are the compounds, wherein R1, R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries A-1 through A-159, where R6 is CHF2.
[0359] In yet another preferred embodiment of the present invention, the compounds of Formula V are the compounds, wherein R1, R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries A-1 through A-159, where R6 is CF3.
[0360] Particularly preferably are the compounds of Formula V, wherein R1, R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries of A-1 to A-159 e, where R6 is H.
[0361] If the meanings of R4 and R5 are different from each other and different from R6, again it is observed that the compounds of Formula V, for which the above combinations of the substituents of R1, R2, R3, R4 and R5, as well as R6 are preferably can be present in the form of different stereoisomers as the -CR4R5R6 group therefore is chiral.
[0362] The same combinations of substituents R1, R2, R3, R4 and R5 as defined in Tables 1 to 153 above, in combination with Table A, entries A-1 to A-159, are also preferred for the compounds of Formula IV.
[0363] Therefore, in a preferred embodiment of the present invention, the compounds of Formula IV are the compounds, wherein R 1 , R 2 , R 3 , R 4 and R 5 are according to any one of Tables 1 to 153 in combination with Table A, entries A-1 through A-159.
[0364] Again it is noted that the wavy lines in generic Formula IV indicate that the R4 and R5 substituents, as well as the R3 substituents and the hydrazone moiety can be present in both possible positions, so that all possible E and Z isomers can be performed.
[0365] The same combinations of substituents R1, R2, R3, R4 and R5 as defined in Tables 1 to 153 above, in combination with Table A, entries A-1 to A-159, are also preferred for the precursors of the compounds of Formula IV, that is, the compounds of Formula I, II and III, provided the substituents are present.
[0366] Therefore, in a preferred embodiment of the present invention, the compounds of Formula III are the compounds, wherein R1, R2 and R3 are as defined in Tables 1 to 153.
[0367] Furthermore, in a preferred embodiment of the present invention, the compounds of Formula II are the compounds, wherein R4 and R5 are as defined in Tables A-1 to A-159.
[0368] Furthermore, in a preferred embodiment of the present invention, the compounds of Formula I are the compounds, wherein R4 and R5 are as defined in Tables A-1 to A-159.
[0369] As indicated above, the compounds of Formula IV can be obtained from the compounds of Formula III through their reaction with the compounds of Formula II.
[0370] In addition to the substituents discussed above, the compounds of Formula III further comprise an X substituent, which represents a leaving group. In principle, any leaving group, which is known in the prior art, for example in the context of nucleophilic substitution reactions, is suitable as substituent X. In the process of preparing the compounds of Formula IV, as described herein, the substituent X of the Formula III compounds is replaced by the amino group of hydrazine so that the substituent is no longer contained in the Formula IV compounds.
[0371] In a preferred embodiment of the present invention, in the compounds of Formula III: - X is halogen, OH, C1-C10 alkoxy, C3-C10 cycloalkoxy, C1-C10 alkyl-C(O)O-, C1 alkyl -C10-S(O)2O-, halalkyl C1-C10-S(O)2O-, phenyl-S(O)2O, tolyl-S(O)2O-, (alkyloxy C1-C10)2P(O)O -, C1-C10 alkylthio, C3-C10 cycloalkylthio, C1-C10 alkyl-C(O)S-, NH2, C1-C10 alkylamino, C1-C10 dialkylamino, morpholine, N-methylpiperazine or aza-C3-C10 cycloalkyl;
[0372] In a more preferred embodiment of the present invention, in the compounds of Formula III: - X is halogen, C1-C4 alkoxy, C1-C4 dialkylamino, morpholine, N-methylpiperazine or aza-cycloalkyl C5-C6.
[0373] Preferably, X is halogen. As halogen, chlorine is particularly preferred.
[0374] With respect to C1-C4 dialkylamino groups, it is observed that the alkyl chains can have identical or different chain lengths. Dimethylamino and diethylamino groups are particularly preferred in accordance with the present invention.
[0375] Furthermore, C1-C4 alkoxy groups, especially C1-C2 alkoxy groups, are particularly preferred according to the present invention.
[0376] The R1, R2 and R3 substituents of the compounds of Formula III have been discussed above above.
[0377] Preferably compounds of Formula III, according to the present invention, are those compounds wherein R1, R2 and R3 are as defined above in any one of Tables 1 to 153 and X is any one of Cl, OCH3 , OCH2CH3, N(CH3)2, N(CH2CH3)2. It should be understood that each combination of the substituents R1, R2 and R3, according to Tables 1 to 153, and X is Cl, OCH3, OCH2CH3, N(CH3)2, N(CH2CH3)2 is suitable for the compounds of Formula III according to the present invention.
[0378] Therefore, in a preferred embodiment of the present invention, the compounds of Formula III are the compounds, wherein R1, R2 and R3 are as defined in Tables 1 to 153, and wherein X is Cl.
[0379] In another preferred embodiment of the present invention, the compounds of Formula III are the compounds, wherein R1, R2 and R3 are as defined in Tables 1 to 153, and wherein X is OCH3.
[0380] In yet another preferred embodiment of the present invention, the compounds of Formula III are the compounds, wherein R1, R2 and R3 are as defined in Tables 1 to 153, and wherein X is OCH2CH3.
[0381] In yet another preferred embodiment of the present invention, the compounds of Formula III are the compounds, wherein R1, R2 and R3 are as defined in Tables 1 to 153, and wherein X is the N(CH3)2 .
[0382] In yet another preferred embodiment of the present invention, the compounds of Formula III are the compounds, wherein R1, R2 and R3 are as defined in Tables 1 to 153, and wherein X is the N(CH2CH3)2 .
[0383] The compounds of Formula II do not contain any other substituents than the R4 and R5 substituents, which were discussed above. Again it is noted, however, that the substituents R4 and R5 can preferably be selected according to Table A above.
[0384] The compounds of Formula II can be obtained from the compounds of Formula I through their reaction with hydrazine.
[0385] The compounds of Formula I do not contain any other substituents than the substituents R4 and R5, which were discussed above above and particularly preferably may be selected according to Table A.
[0386] Regarding hydrazine as a reagent to be reacted with the compounds of Formula I in the process of the present invention, the following is observed.
[0387] Hydrazine (also called diazan) is a compound of Formula H2N-NH2. Although hydrazine primarily can be used in anhydrous form, it is preferably used in the form of an organic solution or that hydrazine is used in the form of the monohydrate H2N-NH2 x H2O or in the form of an aqueous solution of said monohydrate. It is particularly preferred that the hydrazine is used in the form of the monohydrate H2N-NH2 x H2O or in the form of an aqueous solution of said monohydrate.
[0388] If hydrazine is used in a solution in an organic solvent, the solvent is preferably an alcohol, eg isopropanol, ethanol or methanol. Preferably concentrations for alcoholic hydrazine solutions range from 20% to 50% by weight, preferably from 34% to 50% by weight of hydrazine, based on the total weight of the solution. It is particularly preferred that the hydrazine and alcohol are present in a weight ratio of about 1:1 in such alcoholic solutions.
[0389] If hydrazine is used in a solution in an aqueous solvent, the solvent is preferably water, and the concentration usually refers to the concentration of hydrazine monohydrate (H2N-NH2 x H2O). Preferably concentrations for aqueous solutions of hydrazine monohydrate are in the range from 45 to 100% by weight, preferably from 60 to 100% by weight, for example from 80 to 100% or 70 to 90% by weight of hydrazine monohydrate based on the total weight of the solution. Preferably, the hydrazine is used as 100% hydrazine monohydrate or as an aqueous solution of hydrazine monohydrate having a concentration of about 80% by weight of hydrazine monohydrate based on the total weight of the solution.
[0390] Alternatively, hydrazine can be used in the form of a salt. Hydrazine can be easily converted to salts by treatment with mineral or organic acids such as sulfuric acid, hydrochloric acid or acetic acid to provide, for example, salts of the Formula [H2N-NH3]+HSO4-, [H2N -NH3]+Cl- or [H2N-NH3]+[O(C=O)CH3]-, respectively. In certain embodiments preferably, the hydrazine can be used in the form of an acetate or hydrochloride salt in the process according to the present invention. The salt can be added to the reaction mixture as a solid or in solution in an organic or aqueous solvent, for example, in methanol, ethanol, isopropanol or water.
[0391] As indicated above, compounds of Formula V may be present as compounds of Formula Va, Vb or Vc.
[0392] In principle, the same combinations of substituents R1, R2, R3, R4 and R5 as defined in Tables 1 to 153 above, in combination with Table A, entries from A-1 to A-, are also preferably 159 for the compounds of the Formulas Va, Vb and Vc and the compounds obtainable from the compounds of the Formula Vc, i.e. the compounds of the Formulas VI and VIII. However, it is noted that these generic Formulas are predefined above in terms of the R1 substituent so that only specific combinations of R2, R3, R4 and R5 can be derived from the Tables above.
[0393] Compounds of Formula Va, Vb and Vc are included in the definition of compounds of Formula V, if R1 is selected such that R1 is either CN (compound of Formula Vb) or C(O)ORc (compound of Formula Va) or C(O)OH (compound of Formula Vc). If R1 in the compounds of Formula V is C(O)ORc, it is further preferably that Rc is C1-C4 alkyl, for example CH3, CH2CH3, C(CH3)3, or that R1 is C1-aryl C4 alkyl, for example CH2C6H5.
[0394] For the remaining substituents, preferably, it is the same definitions of substituents as discussed above in Tables 1 to 153 in combination with Table A. In addition, R6 preferably is H, CN, CHF2 or CF3.
[0395] Therefore, in a preferred embodiment of the present invention, the compounds of Formula Vb are the compounds, wherein R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries A-1 through A-159, and where R6 is the H.
[0396] Furthermore, in a preferred embodiment of the present invention, the compounds of Formula Va are the compounds, wherein R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries A-1 through A-159, where R6 is H, and where Rc is CH3.
[0397] In another preferred embodiment of the present invention, the compounds of Formula Va are the compounds, wherein R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries A-1 through A-159, and where R6 is H, and where Rc is CH2CH3.
[0398] In another preferred embodiment of the present invention, the compounds of Formula Va are the compounds, wherein R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries A-1 through A-159, and where R6 is H, and where Rc is C(CH3)3.
[0399] In another preferred embodiment of the present invention, the compounds of Formula Va are the compounds, wherein R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries A-1 through A-159, and where R6 is H, and where Rc is CH2C6H5.
[0400] Furthermore, in a preferred embodiment of the present invention, the compounds of Formula Vc are the compounds, wherein R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries A-1 through A-159, and where R6 is the H.
[0401] In addition to the combinations of substituents preferably discussed above, it may be preferable for the compounds of Formula Va, Vb and Vc that: - R2 is CH3 or halomethyl, - R3 is H, - R4 is C1-alkyl C4, C1-C2 haloalkyl or C3 cycloalkyl, wherein the cycloalkyl group is preferably substituted with a substituent selected from CN and C(O)NH2, - R5 is C1-C2 alkyl or C3-C4 cycloalkyl, - or R4 and R5 together with the carbon atom to which they are attached form a 6-membered carbocycle, which is partially or fully halogenated, preferably fluorinated; and - R6 is H.
[0402] In view of the fact that the above compounds of Formulas Va, Vb and Vc are versatile reaction tools for obtaining other pyrazole derivatives, the substituents of the compounds of Formula V, particularly preferably, are selected from such so that R2 is CH3, R3 is H, R6 is H, and the remaining subsequent settings are selected as indicated in one of the lines B-1 to B-30 of Table B. TABLE B

[0403] The lines B-1 to B-5 correspond to the preferred compounds of Formula Vb, the lines B-6 to B-25 correspond to the preferred compounds of Formula Va and the lines B-26 to B-30 correspond to the preferred compounds of Formula Vc which can be used in the process of the present invention.
[0404] As indicated above, compounds of Formula Va and Vb can be obtained from compounds of Formula IV, according to the present invention. Compounds of Formula Vc are obtained from compounds of Formula Va or Vb. Alternatively, compounds of Formula Vc can be directly obtained from compounds of Formula IV, in accordance with the present invention.
[0405] Compounds of Formula Vc can further be converted to compounds of Formula VI, according to the present invention.
[0406] In addition to the substituents discussed above, the compounds of Formula VI further comprise an X1 substituent, which represents a leaving group. In principle, any leaving group, which is known in the prior art, for example in the context of activated carboxylic acid derivatives, is suitable as X1 substituent.
[0407] For example, X1 can be a leaving group, which is based on a peptide coupling reagent. Suitable peptide coupling reagents are described by Han et al., in Tetrahedron 60 (2004) 2,447-2,467. In this regard, N,N'-bis(2-oxo-3-oxazolidinyl)-phosphinic chloride (BOP-Cl) and O-(7-azabenzo-triazol-1-yl)-1,1 hexafluorophosphate ,3,3-tetramethyluronium (HATU) are preferably in accordance with the present invention.
[0408] In addition, X1 can be a leaving group selected from active esters, azide and halogens.
[0409] In a preferred embodiment of the present invention, - X1 is halogen, N3, p-nitrophenoxy or pentafluorophenoxy.
[0410] Preferably, X1 is halogen, in particular Cl.
[0411] Therefore, in a preferred embodiment of the present invention, the compounds of Formula VI are the compounds, wherein R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries A-1 through A-159, where R6 is H, and where X1 is Cl.
[0412] In another preferred embodiment of the present invention, the compounds of Formula VI are the compounds, wherein R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries A-1 through A-159, and where R6 is the H, and where X1 is the N3.
[0413] In another preferred embodiment of the present invention, the compounds of Formula VI are the compounds, wherein R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries A-1 through A-159, and where R6 is H, and where X1 is p-nitrophenoxy.
[0414] In another preferred embodiment of the present invention, the compounds of Formula VI are the compounds, wherein R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries A-1 through A-159, and where R6 is H, and where X1 is pentafluorophenoxy.
[0415] Compounds of Formula VI can further be converted to compounds of Formula VIII.
[0416] In the process of preparing the compounds of Formula VIII, as described above, the X1 substituent of the compounds of Formula VI is replaced by the amine group of the N-(het)arylamine of Formula VII, so that the substituent is no longer contained in the compounds of Formula VIII.
[0417] However, in addition to the remaining substituents discussed above, the compounds of Formula VIII still comprise the N-(het)arylamide group, wherein the amide nitrogen atom is replaced with R1N and the (het)aryl group comprises a substituent U and substituents RP1, RP2 and RP3. The same substituents are also present in compounds of Formula VII, with which compounds of Formula VI can be reacted to provide compounds of Formula VIII.
[0418] In a preferred embodiment of the present invention, - U is N or CH; - RP1, RP2, RP3 are the H; and - R1N is H, C1-C2 alkyl or C1-C2-alkoxy C1-C2 alkyl.
[0419] In particular, the following combinations of substituents U, RP1, RP2, RP3 and R1N, according to Table C, are preferably in the compounds of Formula VII and VIII. TABLE C

[0420] Therefore, in a preferred embodiment of the present invention, the compounds of Formula VII are those compounds, wherein U, RP1, RP2, RP3 and R1N are as defined in any of the lines C-1 to C- 14 of Table C.
[0421] Furthermore, in a preferred embodiment of the present invention, the compounds of Formula VIII are the compounds, wherein R2, R3, R4 and R5 are according to any one of Tables 1 to 153, in combination with Table A, entries A-1 through A-159, and where R6 is the H, and where U, RP1, RP2, RP3 and R1N are as defined in any of the lines C-1 through C-14 of the Table C.
[0422] As indicated above, the present invention also relates to the compounds of Formulas Va, Vb, Vc and VI.
[0423] In one embodiment, the present invention relates to a compound of Formula Va or a salt, stereoisomers, tautomer or N-oxide thereof
- wherein: - R2 is CH3, R3 is H, R4 is CH(CH3)2, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is CHFCH3, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-CN-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-C(O)NH2-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 and R5 together are CH2CH2CF2CH2CH2, and R6 is H; - and wherein: - Rc is C1-C4 alkyl or aryl C1-C4 alkyl, or wherein Rc together with the C(O)O group forms a [C(O)O]-NR4+ salt, [C( O)O]-Ma+ or [C(O)O]-%Ma2+, where Ma is an alkali metal and Mea is an alkaline earth metal; and wherein the R substituents on the nitrogen atom, independently of one another, are selected from H, C1-C10 alkyl, phenyl and phenyl-C1-C4 alkyl.
[0424] If Rc together with the C(O)O group forms a salt, the salt is preferably selected from [C(O)O]-NH4+, [C(O)O]-Na+, [C(O)O]-K+, [C(O)O]-%Ca2+ and [C(O)O]'Mg2+ and, particularly preferably, is [C(O)O]-Na+. If Rc together with the C(O)O group forms a salt, this is to be understood as a carboxylate salt, in which the negative charge is delocalized to the carboxylate group [C(O)O]-.
[0425] If Rc is selected such that the group C(O)ORc is an ester group, preferably, it is that Rc is C1-C4 alkyl or benzyl, more preferably ethyl or tert-butyl.
[0426] It is particularly preferably according to the present invention that Rc is selected in such a way that the C(O)ORc group is an ester group. In this context, C1-C4 alkyl or benzyl ester groups are particularly preferred.
[0427] In another embodiment, the present invention relates to a compound of Formula Vb or a salt, stereoisomers, tautomer or N-oxide thereof
- wherein: - R2 is CH3, R3 is H, R4 is CH(CH3)2, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is CHFCH3, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-CN-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-C(O)NH2-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 and R5 together are CH2CH2CF2CH2CH2, and R6 is H.
[0428] In yet another embodiment, the present invention relates to a compound of Formula Vc or a salt, stereoisomer, tautomer or N-oxide thereof
- wherein: - R2 is CH3, R3 is H, R4 is CH(CH3)2, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is CHFCH3, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-CN-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-C(O)NH2-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 and R5 together are CH2CH2CF2CH2CH2 and R6 is H.
[0429] In yet another embodiment, the present invention relates to a compound of Formula VI or a salt, stereoisomer, tautomer or N-oxide thereof
- wherein: - R2 is CH3, R3 is H, R4 is CH(CH3)2, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is CHFCH3, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-CN-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 is 1-C(O)NH2-cC3H4, R5 is CH3 and R6 is H; or - R2 is CH3, R3 is H, R4 and R5 together are CH2CH2CF2CH2CH2, and R6 is H; - and where: - X1 is an output group.
[0430] Suitable leaving groups include leaving groups, which are known in the prior art in the context of the mentioned carboxylic acid derivatives.
[0431] For example, X1 can be a leaving group, which is based on a peptide coupling reagent. Suitable peptide coupling reagents are described by Han et al., in Tetrahedron 60 (2004) 2,447-2,467. In this regard, N,N'-bis(2-oxo-3-oxazolidinyl)-phosphinic chloride (BOP-Cl) and O-(7-azabenzotriazol-1-yl)-1,1,hexafluorophosphate, 3,3-tetramethyluronium (HATU) are preferably in accordance with the present invention.
[0432] In addition, X1 can be a leaving group selected from active esters, azide and halogens.
[0433] Preferably X1 is selected from halogen, N3, p-nitrophenoxy and pentafluorophenoxy and more preferably X1 is halogen and particularly preferably X1 is Cl.
[0434] As indicated above, the process of the present invention encompasses the preparation of a compound of Formula V by cyclizing a compound of Formula IV by reacting with a reagent comprising an R6 group. Said reaction step provides the benefits of the present invention, i.e. versatile and convenient supply of the compounds of Formula V, therefore preferably ensuring regioselectivity. Preferably, the process of the present invention also includes the preparation of the compounds of Formula IV, so that in particular, a reaction sequence of the following steps (b) and (c) or steps (a), (b) and ( c) is covered by the present invention:

[0435] It is emphasized that the above reaction steps can not only be carried out separately, i.e. under isolation of compounds of Formulas II and IV, but that the reaction steps can also be carried out in a one-step reaction, i.e. , without isolating the compounds of Formulas II and/or IV. One option is for steps (a), (b) and (c) to be combined in a one-step reaction, for example, by combining the compounds of Formula I with hydrazine so that the first compound of Formula II is formed in situ, then the Formula III compound is added to provide the Formula IV compound in situ, and then the reagent comprising R6 is added to provide a Formula V compound. steps (a) and (b) are carried out in a one-step reaction and the compound of Formula IV is isolated and then step (c) is carried out. And yet another option is that step (a) is carried out as a first step and the compound of Formula II is isolated and that steps (b) and (c) are then formed in a reaction of one step.
[0436] In addition, it is emphasized that reactions can be performed on a technical scale. Preferably, the reactants are equally well converted and only small deviations in yield are observed.
[0437] As also discussed above, the compounds of Formula V are versatile reaction tools for the preparation of active agents such as pesticides. For example, if the compounds of Formula V are compounds of Formula Va or Vb, these compounds can be converted to compounds of Formula Vc. Compounds of Formula Vc, which can be obtained from compounds of Formula Va or Vb or as a reaction product of reaction step (c) above, therefore, can still be converted to compounds of Formula VI. In an additional reaction step, compounds of Formula VIII can therefore be obtained. Therefore, the following reaction sequence comprising step (d), preferably step (d) and step (e), and particularly preferably steps (d), (e) and (f), can be carried out later than the above reaction sequence according to the present invention.


[0438] It is noted that also steps (e) and (f) can be carried out as a one-step reaction, so that activated compound VI does not need to be isolated before the amidation reaction.
[0439] The above reaction steps of the process of the present invention will be described below, referring to steps (a), (b), (c), (d), (e) and (f), as indicated above with step (c) being the essential step of the process of the present invention.
[0440] The reaction steps of the process of the present invention as described below are carried out in reaction vessels usual for such reactions, the reactions being carried out in a continuous, semi-continuous or discontinuous manner.
[0441] In general, special reactions will be carried out under atmospheric pressure. However, reactions can also be carried out under reduced pressure.
[0442] The temperatures and durations of reactions can be varied in wide ranges, which the person skilled in the art knows from analogous reactions. Temperatures often depend on the reflux temperature of the solvents. Other reactions are preferably carried out at room temperature, ie at about 25°C, or under ice-cooling, ie at about 0°C. The completion of the reaction can be monitored by known methods by a person skilled in the art, for example, thin layer chromatography or HPLC.
[0443] If not otherwise indicated, the molar ratios of the reactants, which are used in the reactions, are in the range from 0.2:1 to 1:0.2, preferably from 0.5:1 to 1:0.5, more preferably, from 0.8:1 to 1:0.8. Preferably, equimolar amounts are used.
[0444] If not otherwise indicated, the reagents, in principle, can contact each other in any desired sequence.
[0445] The person skilled in the art knows when reactants or reagents are sensitive to moisture, so the reaction should be carried out under shielding gases, such as under a nitrogen atmosphere, and dry solvents should be used.
[0446] The person skilled in the art also knows the best processing of the reaction mixture after completion of the reaction.
[0447] Below, the process of the present invention is described in greater detail.
[0448] The reaction conditions for step (a) of the process are as follows.
[0449] In step (a) of the process of the present invention, a compound of Formula I is reacted with hydrazine to provide a compound of Formula II. Said reaction is a hydrazone formation, which can be carried out under reaction conditions known in the state of the art. In particular, the reaction can be carried out by means of a process, in which hydrazine monohydrate or a hydrazine solution, is reacted with a compound of Formula I in the absence of a solvent or in an aqueous or organic solvent, in which a base or acid catalyst optionally may be present.
[0450] In a preferred embodiment, the reaction is conducted in the absence of a solvent.
[0451] In a preferred embodiment, the reaction is conducted in the absence of a catalyst.
[0452] Suitable reaction temperatures for the reaction are in the range from 0°C to 80°C, preferably from 15°C to 50°C, more preferably from 20 to 25°C C. In certain situations, it may be preferable to start at a lower temperature of 20 to 25°C for about 1 hour and then heat the reaction mixture to a higher temperature of 50 to 80°C. In situations, it may preferably be started at an average temperature of 30 to 50°C for about 1 hour and then stirred the reaction mixture at a temperature of 20 to 25°C.
[0453] Overall reaction times can vary over a wide range, for example, from 1 hour to 3 days. Therefore, it is preferably that the reaction is monitored by means of analytical methods and stopped after complete conversion of the compound of Formula I to Formula II.
[0454] The compound of Formula I is commercially available or can be prepared by methods known in the art.
[0455] As indicated above, hydrazine is preferably provided in the form of the monohydrate or in the form of a solution of said monohydrate in water. Preferably concentrations for aqueous solutions of hydrodizine monohydrate are in the range from 45 to 100% by weight, preferably from 60 to 100% by weight, for example from 80 to 100% or from 70 to 90% by weight of hydrazine monohydrate based on the total weight of the solution. Preferably, the hydrazine is used as 100% hydrazine monohydrate or as an aqueous solution of hydrazine monohydrate having a concentration of about 80% by weight of hydrazine monohydrate based on the total weight of the solution.
[0456] Preferably, hydrazine is used at least in stoichiometric amounts. Preferably, the hydrazine is used in amounts ranging from 1.0 to 10.0 mol, preferably from 1.0 to 2.0 mol, more preferably from 1.0 to 1 .5 mol per mol of the compound of Formula I.
[0457] For practical reasons, it is preferably that the compound of Formula I is added to hydrazine monohydrate or a solution thereof and not vice versa, so that an excess of the compound of Formula I is avoided in comparison with hydrazine in the reaction mixture by mixing the two components.
[0458] If a solvent is present, it is preferably that the solvent is an organic solvent, an aprotic or protic solvent or a mixture thereof. Suitable aprotic solvents include aromatic solvents, ethers or mixtures thereof. Preferred aromatic solvents, for example, are benzene, toluene, xylene (ortho-xylene, meta-xylene or para-xylene), mesitylene, chlorobenzene, 1,2-dichlorobenzene, 1,3-dichlorobenzene, 1,4-dichlorobenzene or its mixtures. Ethers are preferably cyclic and open-chain ethers, in particular diethyl ether, methyl tert-butyl ether (MTBE), 2-methoxy-2-methylbutane, cyclopentylmethyl ether, 1,4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran or mixtures thereof. Protic solvents are usually preferably as solvents. Suitable protic solvents are C1-C4 alkanols such as methanol, ethanol, propanol and isopropanol, C2-C4 alkandiols such as ethylene glycol or propylene glycol, and ether alkanols such as diethylene glycol and mixtures thereof. Particularly preferred are C1-C4 alkanols, for example methanol, ethanol, isopropanol, butanol, or mixtures thereof, in particular ethanol.
[0459] The reaction can also be carried out in the presence of an acidic or basic catalyst. Preferred acid catalysts include HCl in H2O, HCl in MeOH, HCl in dioxane; H2SO4, H3PO4 and salts of H2SO4 and H3PO4; aromatic sulfonic acids such as toluenesulfonic acid; alkylsulfonic acids, such as methylsulfonic acid; aromatic carboxylic acids such as benzoic acid; alkylcarboxylic acids such as acetic acid; rare earth metal salts; and Lewis acids such as BF3, BF3 x OEt2, BF3 x SMe2, TiCl4, Ti(OiPr)4. A preferred acid catalyst is acetic acid. Basic catalysts preferably include BaO, CaO, MgCO3, CaCO3, Na2CO3, K2CO3 and NEt3. A preferred base catalyst is BaO.
[0460] The acid or base catalyst is preferably used in amounts ranging from 0.001 to 10 mol, preferably from 0.01 to 0.5 mol, more preferably from 0. 02 to 0.3 mol per mol of the compound of Formula I. For acid catalysts, amounts in the range from 0.05 to 0.2 mol per mol of the compound of Formula I may be preferable. For basic catalysts, amounts in the range from 0.15 to 0.25 or from 0.2 to 0.3 mol per mol of the compound of Formula I may be preferable.
[0461] The reaction conditions for step (b) of the process of the present invention are as follows.
[0462] In step (b), a compound of Formula II is reacted with a compound of Formula III to obtain a compound of Formula IV. Said reaction corresponds to a substitution reaction in an α,β-unsaturated carbonyl compound comprising a leaving group at the β position with a hydrazone acting as a nucleophile. The reaction can be carried out under reaction conditions known in the state of the art. In particular, the reaction can be carried out by means of a process, in which the compound of Formula II is reacted with a compound of Formula III in the absence of a solvent or in an organic solvent, in which a basic catalyst optionally can be present.
[0463] Suitable reaction temperatures for the reaction are in the range from -20°C to 50°C, preferably from 15°C to 40°C, most preferably from 20 to 25 °C. It is normally preferred that the compounds of Formulas II and III are mixed together at temperatures below 0°C, preferably about -20°C, and that the mixture then be allowed to warm to a temperature. reaction temperature defined above.
[0464] Overall reaction times can vary over a wide range, eg from 1 hour to 1 day, preferably from 3 to 12 hours.
[0465] The compound of Formula II can be supplied as the crude product of step (a), that is, without the formation of any purification steps before step (b), or as part of the reaction mixture obtained in step (a ), to which the compound of Formula III can then be added.
[0466] The compound of Formula III is commercially available or can be prepared by methods known in the art.
[0467] Preferably, the compound of Formula III is used in amounts ranging from 0.1 to 10.0 mol, preferably from 0.8 to 1.5 mol, more preferably from from 0.9 to 1.3 mol per mol of the compound of Formula II.
[0468] If a solvent is present, it is preferably that the solvent is an organic solvent, an aprotic or protic solvent or a mixture thereof. Suitable aprotic solvents include aromatic solvents, ethers or mixtures thereof. Preferred aromatic solvents, for example, are benzene, toluene, xylene (ortho-xylene, meta-xylene or para-xylene), mesitylene, chlorobenzene, 1,2-dichlorobenzene, 1,3-dichlorobenzene, 1,4-dichlorobenzene or its mixtures. Ethers are preferably cyclic and open-chain ethers, in particular diethyl ether, methyl tert-butyl ether (MTBE), 2-methoxy-2-methylbutane, cyclopentylmethyl ether, 1,4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran or mixtures thereof. An especially suitable open-chain ether, for example, is MTBE. Protic solvents are usually preferably as solvents. Suitable protic solvents are C1-C4 alkanols such as methanol, ethanol, propanol and isopropanol, C2-C4 alkandiols such as ethylene glycol or propylene glycol, and ether alkanols such as diethylene glycol and mixtures thereof. Particularly preferred are C1-C4 alkanols, for example methanol, ethanol, isopropanol, butanol, or mixtures thereof, in particular ethanol.
[0469] In principle, the reaction can be easily carried out without needing to use a catalyst. However, the reaction can also be carried out in the presence of a basic catalyst. Basic catalysts preferably include BaO, CaO, MgCO3, CaCO3, Na2CO3, K2CO3 and NEt3.
[0470] If a basic catalyst is used, preferably it is amounts in the range from 0.01 to 2.0 mol, preferably from 1.0 to 2.0 mol, per mol of the compound of Formula II.
[0471] The reaction conditions for step (c) of the process of the present invention are as follows.
[0472] In step (c), a compound of Formula IV is reacted with a reagent comprising an R6 group to provide a compound of Formula V. The reaction conditions are described below. In particular, the reaction can be carried out by means of a process, in which the compound of Formula IV is reacted with the reaction compound comprising the R6 group in the presence of a solvent, in which an acid catalyst or a metal catalyst can optionally be present.
[0473] Solvent selection depends on the type of reagent comprising the R6 group. In general, organic solvents including aprotic solvents such as aromatic solvents, ethers or mixtures thereof, and protic solvents can be used. Preferred aromatic solvents, for example, are benzene, toluene, xylene (ortho-xylene, meta-xylene or para-xylene), mesitylene, chlorobenzene, 1,2-dichlorobenzene, 1,3-dichlorobenzene, 1,4- dichlorobenzene or mixtures thereof. Ethers are preferably cyclic and open-chain ethers, in particular diethyl ether, methyl tert-butyl ether (MTBE), 2-methoxy-2-methylbutane, cyclopentylmethyl ether, 1,4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran or mixtures thereof. Preferred protic solvents are C1-C4 alkanols such as methanol, ethanol, propanol and isopropanol, C2-C4 alkandiols such as ethylene glycol or propylene glycol, and ether alkanols such as diethylene glycol and mixtures thereof. Particularly preferred are C1-C4 alkanols, for example methanol, ethanol, isopropanol, butanol, or mixtures thereof.
[0474] If the reagent is the reducing agent, preferably an ionic hydride donor, organic protic solvents may be preferable. Suitable protic solvents include C1-C4 alkanols such as methanol, ethanol, propanol and isopropanol, C2-C4 alkandiols such as ethylene glycol or propylene glycol, and ether alkanols such as diethylene glycol and mixtures thereof. Particularly preferred are C1-C4 alkanols, for example methanol, ethanol, isopropanol, butanol, or mixtures thereof, in particular methanol, ethanol and isopropanol. If the reducing agent is a higher reactivity ionic hydride donor, as in the case of Li+[AlH4]-, it may preferably be that the solvent is an aprotic organic solvent, for example an ether solvent such as dham ether. diethyl, methyl-tert-butyl ether (MTBE), 2-methoxy-2-methylbutane, cyclopentylmethyl ether, 1,4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran or mixtures thereof. Ether solvents, such as those listed above, are also preferred if the reagent is a non-ionic hydride donor.
[0475] On the other hand, protic solvents as mentioned above are again preferred, if electron donors are used in combination with protons to act as a reducing agent since protons are needed for in situ radical formation of hydrogen.
[0476] If the reagent is an organometallic agent, then aprotic organic solvents are usually preferred. Suitable aprotic solvents include aliphatic hydrocarbons, cycloaliphatic hydrocarbons, halogenated alkanes, aromatic hydrocarbons, open chain ethers, cyclic ethers, esters, aliphatic or alicyclic carbonates, especially aromatic solvents and cyclic and open chain ethers. Preferred aprotic solvents are cyclic and open-chain ethers. Preferred open-chain ethers are diethyl ether, methyl tert-butyl ether (MTBE), 2-methoxy-2-methylbutane and cyclopentylmethyl ether. Preferred cyclic ethers are tetrahydrofuran, 2-methyltetrahydrofuran and 1,4-dioxane.
[0477] If the reagent is a nucleophilic reagent, protic and aprotic organic solvents can be used. Protic solvents such as C1-C4 alkanols, in particular methanol, ethanol and isopropanol, may also be preferred.
[0478] Reaction temperatures also depend on the type of reagent comprising the R6 group.
[0479] If the reagent is a reducing agent, the reaction temperatures may be in the range from 20°C to 50°C, preferably from 10°C to 30°C, most preferably at from 20°C to 25°C. In certain situations, it may be preferable to start the reaction at a higher temperature of 30°C to 50°C and then keep the reaction at room temperature.
[0480] If the reagent is an organometallic reagent, lower reaction temperatures of -78°C to 0°C may be suitable. Alternatively, the reaction temperature may be in the range from 0°C to 50°C °C, preferably from 10°C to 30°C, more preferably from 20 to 25°C. In certain situations, it may be preferable to start at a temperature below about -78°C , -20°C or 0°C for about 1 hour and then allow the reaction mixture to warm to a temperature of 0°C to 25°C.
[0481] If the reagent is a nucleophilic reagent, the reaction temperatures can be in the range from 0°C to 50°C, preferably from 10°C to 30°C, most preferably from from 20 to 25°C. Alternatively, it may preferably be that the reaction mixture is heated, for example, to a reaction temperature from 50°C to 80°C.
[0482] Total reaction times may vary over a wide range, preferably from 1 hour to 4 days, for example, from 4 hours to 8 hours, from 10 to 18 hours, from 24 hours to 48 hours, or from 2 days to 4 days. Therefore, it is preferably that the reaction is monitored by means of the analytical methods and stopped after complete conversion of the compound of Formula IV to the compound of Formula V.
[0483] The compound of Formula IV can be supplied as a crude product from step (b), that is, without the formation of any purification step prior to step (c), or as part of the reaction mixture obtained from step ( b) to which the reagent comprising the R6 group can then be added.
[0484] The reagent comprising the R6 group is preferably used at least in stoichiometric amounts, for example, in amounts ranging from 1.0 to 10.0 mol, preferably from 1 0.0 to 2.0 mol per mol of the compound of Formula IV. If the reagent comprises an amount greater than a transferable R6 group, it may also suffice to use substoichiometric amounts, for example in the range from 0.1 to less than 1.0 mol, preferably 0.5 to less than 1.0 mol per mol of the compound of Formula IV. In principle, the reagent, therefore, can be used in amounts ranging from 0.1 to 10.0 mol per mol of the compound of Formula IV. Preferably, the reagent is used in amounts from 0.8 to 2.0 mol, more preferably from 1.0 to 1.5 mol, per mol of the compound of Formula IV.
[0485] If the reagent comprising the R6 group is in gaseous form, for example in the case of dihydrogen, the reaction agent is normally used in an excess by running the reaction in an atmosphere of the reagent comprising the R6 group. A given pressure can be applied which preferably does not exceed 100 bar for practical reasons.
[0486] The reagent comprising the R6 group can be added all at once or in portions. In particular, for the reagent being a reducing agent, for example an ionic hydride donor such as Na+[B(CN)H3]-, it is preferably that the reagent is provided in two or three portions.
[0487] If the amount of reagent comprising the R6 group is used at one time, it is preferably for practical reasons that the compound of Formula IV is added to the reagent comprising the R6 group.
[0488] Similarly, if the amount of the reagent comprising the R6 group is used in portions, it is preferably that the compound of Formula IV is added to the first portion of the reducing agent. Typically, about half the amount of the reagent comprising the R6 group is used in this context. The mixture is then stirred for a set reaction time, for example 10 to 18 hours, and one or two additional portions of the reagent are added later, so that the full amount of the reagent is finally added to the reaction. The reaction mixture is then further stirred for a set reaction time, eg 10 to 18 hours, 12 to 24 hours, or 3 to 4 days.
[0489] The preferred pH values for the reaction of compounds of Formula IV with the reagent comprising the R6 group, for example, an ionic hydride donor such as Na+[B(CN)H3]-, are in the range from 4 to 6.
[0490] In general, the reaction can be carried out in the presence of an acid catalyst. This is particularly preferably if the reagent comprising the R6 group is a reducing agent or a nucleophilic agent. Preferred acid catalysts include HCl in H2O, HCl in MeOH, HCl in dioxane; H2SO4, H3PO4 and salts of H2SO4 and H3PO4; aromatic sulfonic acids such as toluenesulfonic acid; alkylsulfonic acids, such as methylsulfonic acid; aromatic carboxylic acids such as benzoic acid; alkylcarboxylic acids such as acetic acid; rare earth metal salts; and Lewis acids such as BF3, BF3 x OEt2, BF3 x SMe2, TiCl4, Ti(OiPr)4. Preferred acid catalysts further include aromatic sulfonic acids such as toluene sulfonic acid; alkylsulfonic acids, such as methylsulfonic acid; aromatic carboxylic acids such as benzoic acid; alkylcarboxylic acids such as acetic acid; haloalkylcarboxylic acids such as trifluoroacetic acid and mineral acids such as hydrogen chloride or sulfuric acid in methanol. A preferred acid catalyst is acetic acid or HCl in MeOH. Acetic acid is particularly preferred.
[0491] The acid catalyst is preferably used in amounts ranging from 0.001 to 10 mol, preferably from 1.0 to 5.0 mol, eg 1.0 to 2.0 mol or 2.0 to 4.0 mol, per mol of the compound of Formula IV. For acetic acid it is preferably 1.0 to 3.0 mol per mol of the compound of Formula IV and for HCl in MeOH it is preferably 1.0 to 5.0 mol per mol. mole of the compound of Formula IV.
[0492] Alternatively or additionally, a metal catalyst may be present in the reaction mixture. Suitable metal catalysts include Cu, Pd, Pt, Ni, Fe, Rh, Ru as elements or in the form of a salt, neat or in an inert carrier. Suitable catalysts include Rayne nickel, Pd/C, Pt/C and the like. The metal catalysts are preferably selected from the group consisting of Rayne nickel, Pd/C, Pt/C, Ru/C, Rh/C and PtO2, especially Rayne nickel, Pd/C, Pt /C and PtO2.
[0493] The resulting compounds of Formula V, which can be obtained according to step (c) of the process of the present invention, can be purified by methods known in the state of the art, for example, by distillation, if the Formula Va esters are prepared.
[0494] The reaction conditions for step (d) of the process of the present invention are as follows.
[0495] In step (d), a compound of Formula Va or Vb is converted to a compound of Formula Vc. Usually, such a reaction can be understood as a hydrolysis reaction once an ester or a nitrile is hydrolyzed to provide the free acid. However, other conversion reactions of esters or nitriles to free acids, such as the conversion of tert-butyl esters to free acids by the addition of trifluoroacetic acid are also encompassed by the present invention.
[0496] If the reaction according to step (d) is a hydrolysis reaction, the reaction can be carried out by means of a process, in which the compound of Formula Va or Vb is reacted with water, for example, in in the presence of a base or in the presence of an acid, or by means of a process, in which the compound of Formula Va or Vb is reacted with a water-soluble base, preferably an oxo-base, in an aqueous solvent, or by means of of a process, in which the compound of Formula Va or Vb is reacted with a hydroxide in an aqueous or organic protic solvent. Such hydrolysis reactions can be carried out according to procedures known in the state of the art.
[0497] Preferably according to the present invention, step (d) is carried out by dissolving a compound of Formula Va in a protic solvent, an aqueous solvent such as water or in a protic organic solvent such as a C1 alkanol -C4, for example methanol, ethanol or isopropanol, and adding a hydroxide.
[0498] Suitable hydroxides include alkali metal hydroxides such as lithium, sodium or potassium hydroxide, and mixtures thereof. Sodium hydroxide is particularly preferred.
[0499] Preferably, sodium hydroxide is used in amounts from 1 to 10 mol, preferably from 2.0 to 6.0 mol, for example from 2.0 to 3 .0 mol or from 5.0 to 6.0 mol per mol of the compound of Formula Va.
[0500] Suitable reaction temperatures can range from 20 to 100°C, for example from 20 to 25°C or from 50 to 100°C.
[0501] Reaction times can vary from 1 hour to 2 days, for example, from 1 to 3 hours or from 12 hours to 24 hours or from 1 to 2 days.
[0502] The conversion of compounds of Formula Va to compounds of Formula Vc can be enhanced, and complete conversion can be more easily ensured if the alcohol, which is formed by hydrolysis of compounds of Formula Va, is removed from the reaction mixture, for example, through distillation.
[0503] The conversions of compounds of Formula Vb into compounds of Formula Vc are advantageously carried out in an acidic medium, preferably, in the presence of H2SO4 or in the presence of HCl in MeOH. As intermediate compounds, imino ester compounds are formed which are then hydrolyzed to the desired acids of Formula Vc.
[0504] The resulting compounds of Formula Vc can be purified by methods known in the art, for example, by crystallization under suitable pH conditions.
[0505] The reaction conditions for steps (e) and (f) of the process are as follows.
[0506] In step (e), the compound of Formula Vc is activated through its conversion to the activated acid derivative of Formula VI.
[0507] Suitable peptide coupling reagents, which can be used to introduce the X1 leaving group of compounds of Formula VI from compounds of Formula V, are described by Han et al., in Tetrahedron 60 (2004) 2447 -2,467. In this regard, N,N'-bis(2-oxo-3-oxazolidinyl)-phosphinic hydrochloride (BOP-Cl) and O-(7-azabenzo-triazol-1-yl)-1,1,hexafluorophosphate, 3,3-tetramethyluronium (HATU) are preferably in accordance with the present invention.
[0508] In addition to the conversion of compounds of Formula Vc into activated acid derivatives of Formula VI by means of these peptide coupling reagents, the way in which leaving groups such as halogen, N3, p has also been described in the prior art. -nitrophenoxy and pentafluorophenoxy can be introduced into compounds of Formula Vc to provide the corresponding compounds of Formula VI. In this context, reference is made to publications WO 2009/027393 and WO 2010/034737.
[0509] The compound of Formula VI can be directly converted to a compound of Formula VIII or isolated. However, preferably, the compound of Formula VI is directly converted to the compound of Formula VIII.
[0510] The conversion of compounds of Formula VI into compounds of Formula VIIII by reacting compounds of Formula VI with compounds of Formula VIII has been previously described in publications WO 2009/027393 and WO 2010/034737. EXAMPLES (I) CHARACTERIZATION
[0511] The characterization can be performed by means of coupled high performance liquid chromatography / mass spectrometry (HPLC / MS), by NMR or by their melting points.
[0512] HPLC / MS: the following methods (A), (B), (C) and (D) were used, and will still be referred to below: (A) Phenomenex Kinetex 1.7 μm XB-C18 100A; 50 x 2.1 mm; Mobile phase: A: water + 0.1% trifluoroacetic acid (TFA); B: acetonitrile (MeCN) + 0.1% TFA; gradient: B from 5 to 100% in 1.50 minutes; 100% B in 0.20 min; flow: from 0.8 to 1.0 mL/min in 1.50 minutes at 60°C. MS-method: ESI positive. (B) The gradient was from 10 to 80% B in 1.15 min with a retention of 90% B for 0.4 min, from 80 to 10% B in 0.01 min and then retained at 10% B for 0.54 min (flow rate 1.0 ml/min)). Mobile phase A was 0.0375% TFA in water, mobile phase B was 0.018% TFA in MeCN. The column temperature was 40°C. The column used for chromatography was a 2.1 x 30 mm Halo C18 column (2.7 µm particles). MS-method: ESI positive. (C) Gradient was B from 10 to 80% in 1.15 min with a retention of B to 90% for 0.4 min, B from 80 to 10% in 0.01 min and then retained at 10% B for 0.54 min (1.0 ml/min flow rate)). Mobile phase A was 0.0375% TFA in water, mobile phase B was 0.018% TFA in MeCN. The column temperature was 40°C. The column used for chromatography was 2.0 x 30 mm phenomenex Luna-C18 column (3 µm particles). MS-method: ESI positive. (D) The gradient was from B to 5 to 95% in 0.7 min, B from 95-95% in 0.45 min, B from 95 to 5% in 0.01 min and then retained at B at 0% for 0.44 min (flow rate 1.5 ml/min). Mobile phase A was 0.0375% TFA in water, mobile phase B was 0.018% TFA in MeCN. The column temperature was 40°C. The column used for chromatography was a Chromolith Flash Rp -18e 25-2mm column. MS-method: ESI positive.
[0513] 1H NMR: Signals are characterized by chemical shift (ppm) versus tetramethylsilane, by their multiplicity and by their integral number (relative number of hydrogen atoms supplied). The following abbreviations are used to characterize the multiplicity of signals: m = multiplett, q = quartett, t = triplett, d = doublet and s = singlett.
[0514] The abbreviations used are: h for hour(s), min for minute(s) and room temperature for 20 to 25°C. (II) PREPARATION EXAMPLES EXAMPLE 1 STEP A - 1-Cyclohexylpropan hydrazone -2-one.
[0515] A mixture of 1-cyclohexylpropan-2-one (10 g), hydrazine monohydrate (4.3 g), barium oxide (2.8 g) and ethanol (100 ml) was refluxed for 14 h . After cooling to room temperature, diethyl ether was added (120 ml). The mixture was filtered and the filtrate evaporated to give the crude title compound (9.0 g, ca. 82% yield). EXAMPLE 2 STEP B - Ethyl 2-[[2-(2-cyclohexyl-1-methyl-ethylidene)hydrazino]methylene]-3-oxo-butanoate.
[0516] Crude 1-cyclohexylpropan-2-one hydrazone (9.0 g) in ethanol (20 mL) was added to ethyl 2-(ethoxymethylene)-3-oxo-butanoate (11 g) in ethanol (80 ml) at -20°C within 40 min. After 30 min, the mixture was stirred at room temperature overnight and directly used in the next step. EXAMPLE 3 STEP C - Ethyl 1-(2-cyclohexyl-1-methyl-ethyl)-5-methyl-pyrazole-4-carboxylate.
[0517] Acetic acid (4.3 mL) was added to the reaction mixture from Step 2. Sodium cyanoborohydride (2.4 g) was added portionwise over 30 min at room temperature. After stirring overnight, more acetic acid was added (2.5 ml) and more sodium cyanoborohydride (1.1 g). After stirring overnight, again more acetic acid was added (3 ml) and more sodium cyanoborohydride (2.0 g) and the mixture was stirred at 50°C for 3 hours and then concentrated in vacuo. . Water was added (80 ml) to the residue and the aqueous phase was extracted three times with tert-butylmethyl ether. The combined organic extracts were washed with water, dried over sodium sulfate and concentrated in vacuo to furnish the crude title compound (17 g, ca. 80% purity, ca. 84% yield over 2 steps). EXAMPLE 4 STEP D - 1-(2-Cyclohexyl-1-methyl-ethyl)-5-methyl-pyrazole-4-carboxylic acid.
[0518] A mixture of crude ethyl 1-(2-cyclohexyl-1-methyl-ethyl)-5-methyl-pyrazole-4-carboxylate (17 g, about 80% purity), aqueous hydroxide solution sodium (2M, 56ml) and ethanol (150ml) was stirred at room temperature for 2 days and then concentrated in vacuo. Water was added to the residue and the aqueous phase was extracted three times with tert-butylmethyl ether. Concentrated hydrochloric acid was added under ice-cooling to adjust the pH to about 4. The precipitate was filtered off, washed with water, triturated with tert-butyl methyl ether and dried in vacuo to obtain 5.3 g, about 43% yield, 30% yield over all 4 steps. 1H NMR (d6-DMSO): 7.76 (s, 1H), 4.46 (m, 1H), 2.49 (s, 3H), 1.84 (m, 1H), 1.70 (d, 11.3 Hz, 1H), from 1.66 to 1.43 (M, 5H), 1.31 (d, 6.6 Hz, 3H), 1.09 (m, 3H), 0.89 (m , 3H).
[0519] According to the above 4-step reaction procedure for preparing compounds of Formula Vc by performing: - step (a) to provide compounds of Formula II (Example 1), - step (b ) to provide the compounds of Formula IV (Example 2), - from step (c) to provide the compounds of Formula Va (Example 3), and - from step (d) to provide the compounds of Formula Vc (Example 4),
[0520] A variety of compounds of Formula Va and Vc have been prepared. Relevant substituents of compounds of Formula Vc and their precursors are listed in Table D. In addition, yields and analytical HPLC/MS data are provided. The relevant reaction scheme is again illustrated below: - Step (a):

TABLE D


[0521] The reaction procedure of Examples 1 to 4 refers to compounds with a substitution pattern according to entry 13 of Table D.
[0522] The compounds according to the remaining entries were prepared analogously or according to the reaction conditions exemplified below refer to certain entries in Table D. The reaction conditions exemplified below are not limited to the entries in the Table D to which they refer, but were also suitable for the preparation of other compounds described in Table D.
[0523] It is observed that steps (a) and (b), steps (b) and (c) were also carried out in a one-step reaction in the preparation of certain compounds.
[0524] The following reaction conditions for steps (a), (b), (c) and (d) are relevant for the preparation of the compounds listed above (abbreviations: rt = room temperature, ie from 20 to 25 °C, rfx = reflux temperature, ie, boiling point of solvent, MeOH = methanol, EtOH = ethanol, AcOH = acetic acid, MTBE = methyl-tert-butyl ether, eq = equivalent).

权利要求:
Claims (18)
[0001]
1. PROCESS FOR THE PREPARATION OF A pyrazole COMPOUND of Formula V, or a salt, stereoisomer, tautomer or N-oxide thereof
[0002]
2. Process according to claim 1, characterized in that: - R1 is H, halogen, CN, NO2, C1-C10 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1 , 2 or 3 identical or different Rx substituents, C(Y)ORc, S(O)mRd, S(O)mY1Rd, C3-C12 cycloalkyl, aryl or hetaryl, where the cyclic moieties may be unsubstituted or may be substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the radicals Ry and Rx; - wherein Rc is H, C1-C4 alkyl or aryl C1-C4 alkyl, or wherein Rc together with the C(Y)O group forms a [C(Y)O]-NH4+ salt, [C(Y) )O]-Ma+ or [C(Y)O]-1/2Ma2+, where Ma is an alkali metal and Mea is an alkaline earth metal; - where Rd is C1-C4 alkyl, C3-C6 cycloalkyl, aryl or hetaryl; - where Y is the O; and - wherein Y1 is O or NR1a, wherein R1a is C1-C4 alkyl, C3-C6 cycloalkyl, aryl or hetaryl; - and in which, preferably, - R 1 is CN, C(Y)ORc, - in which Y is O and Rc is C 1 -C 4 alkyl or benzyl.
[0003]
Process according to any one of claims 1 to 2, characterized in that: - R2 is C1-C10 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1, 2 or 3 identical or different Rx substituents, - C3-C12 cycloalkyl, aryl or hetaryl, where the cyclic moieties can be unsubstituted or can be substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the radicals Ry and Rx; - and wherein, preferably, - R 2 is C 1 -C 4 alkyl, which may be unsubstituted, or may be partially or fully halogenated.
[0004]
Process according to any one of claims 1 to 3, characterized in that: - R3 is H, C1-C10 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1, 2 or 3 identical or different Rx substituents, - C3-C12 cycloalkyl, aryl or hetaryl, wherein the cyclic moieties can be unsubstituted or can be substituted with 1, 2, 3, 4 or 5 identical or different substituents selected from the radicals Ry and Rx; - and where, preferably, - R3 is H.
[0005]
5. Process according to any one of claims 1 to 4, characterized in that R2 and R3 are different from each other.
[0006]
6. Process according to any one of claims 1 to 5, characterized in that: - R4 is selected from C1-C10 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1, 2 or 3 identical or different Rx substituents, and - C3-C10 cycloalkyl, which may be unsubstituted or may be substituted with 1, 2, 3, 4, or 5 identical or different Ry substituents; and - R5 is selected from C1-C10 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1, 2 or 3 identical or different Rx substituents, and - C3-C10 cycloalkyl, which can be unsubstituted or can be substituted with 1, 2, 3, 4, or 5 identical or different Ry substituents; - and wherein, preferably, - R4 is selected from C1-C4 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1 or 2 identical or different Rx substituents, wherein Rx is selected from CN and C(O)NH2, and - C3-C6 cycloalkyl, which may be unsubstituted or may be substituted with 1, 2 or 3 identical or different Ry substituents, where Ry is selected from halogen , CN and C(O)NH2; and - R5 is selected from C1-C4 alkyl, which may be unsubstituted, may be partially or fully halogenated, or may be substituted with 1 or 2 identical or different Rx substituents, wherein Rx is selected from CN and C(O)NH2, e - C3-C6 cycloalkyl, which may be unsubstituted or may be substituted with 1, 2 or 3 identical or different Ry substituents, where Ry is selected from halogen, CN and C(O) NH2.
[0007]
Process according to any one of claims 1 to 6, characterized in that the reagent comprising the R6 group is: (i) a reducing agent, where R6 is H, (ii) an organometallic reagent, where R6 is selected from C1-C6-fluoroalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl-C1-C2 alkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenyl -C1-C2 alkyl, heterocyclyl, heterocyclyl C1-C2 alkyl, aryl, aryl C1-C2 alkyl, hetaryl, hetaryl C1-C2 alkyl, wherein the carbon chains or cyclic moieties may be unsubstituted, partially or fully substituted with substituents identical or different Rx, or (iii) a nucleophilic reagent of Formula H-R6, Ma+R6- or %Mea2+R6-, where Ma is an alkali metal and Mea is an alkaline earth metal, and where R6 is selected from CN, ORa, SRa, NReRf, and groups of General Formula (i)
[0008]
Process according to any one of claims 1 to 7, characterized in that: - R6 is selected from H, CN and C1-C2 fluoroalkyl; - and where, preferably, - R6 is H.
[0009]
Process according to any one of claims 1 to 8, characterized in that it further comprises the step of preparing the α,β-unsaturated hydrazone-substituted carbonyl compound of Formula IV
[0010]
10. Process according to claim 9, characterized in that: - X is halogen, OH, C1-C10 alkoxy, C3-C10 cycloalkoxy, C1-C10 alkyl-C(O)O-, C1-C10-S alkyl (O)2O-, C1-C10 haloalkyl-S(O)2O-, phenyl-S(O)2O, tolyl-S(O)2O-, (C1-C10 alkyloxy)2P(O)O-, C1 alkylthio -C10, C3-C10 cycloalkylthio, C1-C10 alkyl-C(O)S-, NH2, C1-C10 alkylamino, C1-C10 dialkylamino, morpholine, N-methylpiperazine or C3-C10 aza cycloalkyl; - and in which, preferably, - X is halogen, C1-C4 alkoxy, C1-C4 dialkylamino, morpholine, N-methylpiperazine or C5-C6 aza-cycloalkyl.
[0011]
Process according to any one of claims 9 to 10, characterized in that it further comprises the step of preparing the hydrazone compound of Formula II
[0012]
Process according to any one of claims 1 to 11, characterized in that the compound of Formula V is a compound of Formula Va or Vb
[0013]
Process according to any one of claims 1 to 12, characterized in that the process further comprises the step of converting a compound of Formula Vc into a compound of Formula VI
[0014]
14. Process according to claim 13, characterized in that the process further comprises the step of converting the compound of Formula VI into a compound of Formula VIII
[0015]
15. Process according to claim 14, characterized in that: - U is N or CH; - RP1, RP2, RP3 are the H; and - R1N is H, C1-C2 alkyl or C1-C2-alkoxy C1-C2 alkyl.
[0016]
16. COMPOUND, of Formula Va or a salt thereof, stereoisomers, tautomer or N-oxide
[0017]
17. COMPOUND, of Formula Vc or a salt, stereoisomer, tautomer or N-oxide thereof
[0018]
18. COMPOUND, of Formula IV or a salt, stereoisomer, tautomer or N-oxide thereof - characterized in that: - R1 is CN, C(O)OCH3, C(O)OCH2CH3, C(O)OC(CH3)3, C(O)OCH2C6H5, or COOH; - R2 is CH3, R3 is H, and - R4 is CH(CH3)2, and R5 is CH3; or - R4 is CHFCH3, and R5 is CH3; or - R4 is 1-CN-cC3H4, and R5 is CH3; or - R4 is 1-C(O)NH2-cC3H4, and R5 is CH3; or - R4 and R5 together are CH2CH2CF2CH2CH2.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112016030863B1|2021-05-04|process for preparing a compound and compounds

---

ES2795874T3|2020-11-25|Catalytic hydrogenation process to prepare pyrazoles

---

ES2882543T3|2021-12-02|Process for the preparation of 4-amino-pyridazines

---

JP5271264B2|2013-08-21|Regioselective palladium-catalyzed synthesis of benzimidazole and azabenzimidazole

---

AU2004279808B2|2010-04-22|Process for the preparation of N-amino substituted heterocyclic compounds

---

BR122019027518B1|2021-01-19|PROCESSES FOR THE PREPARATION OF A COMPOUND, DICLOROPYRIDAZINE AMINE COMPOUND AND DICLOROPYRIDAZINE AMINE COMPOUND MIXTURE

同族专利:

---

公开号 | 公开日

---

US20170210712A1|2017-07-27|

---

US20190194141A1|2019-06-27|

---

RU2017106265A3|2019-02-25|

---

UA121395C2|2020-05-25|

---

MX2017001462A|2017-05-23|

---

AU2015295287A1|2017-02-16|

---

JP6625610B2|2019-12-25|

---

WO2016016369A1|2016-02-04|

---

EP3174858A1|2017-06-07|

---

PL3174858T3|2019-10-31|

---

RU2017106265A|2018-08-30|

---

IL249730A|2019-12-31|

---

CN106573893B|2020-06-09|

---

ES2741831T3|2020-02-12|

---

ZA201701415B|2019-06-26|

---

US10414733B2|2019-09-17|

---

TR201909606T4|2019-07-22|

---

PT3174858T|2019-07-23|

---

US10513498B2|2019-12-24|

---

US20180086715A9|2018-03-29|

---

CA2954212A1|2016-02-04|

---

KR20170036094A|2017-03-31|

---

EP3174858B1|2019-04-17|

---

AU2015295287B2|2019-07-04|

---

DK3174858T3|2019-07-15|

---

JP2017522342A|2017-08-10|

---

CN106573893A|2017-04-19|

---

RU2712192C2|2020-01-24|

---

IL249730D0|2017-02-28|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4728355A|1985-10-10|1988-03-01|Fmc Corporation|Pyridazinylurea plant regulators|

---

TW406075B|1994-12-13|2000-09-21|Upjohn Co|Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds|

---

CN1100778C|1995-07-06|2003-02-05|诺瓦蒂斯有限公司|Pyrrolopyrimidines and processes for preparation thereof|

---

US6258822B1|1997-08-06|2001-07-10|Abbott Laboratories|Urokinase inhibitors|

---

WO1999064402A1|1998-06-05|1999-12-16|EGIS Gyógyszergyár Rt.|Process for the preparation of a 3-pyridazinone- 4-substituted amino- 5-chloro- derivative|

---

CZ2002323A3|1999-07-28|2002-05-15|Aventis Pharmaceuticals Products Inc.|Substituted oxoazaheterocyclyl compounds and pharmaceutical preparations in which they are comprised|

---

WO2002100352A2|2001-06-12|2002-12-19|Merck & Co., Inc.|Nr2b receptor antagonists for the treatment or prevention of migraines|

---

JP2007326784A|2006-06-06|2007-12-20|Sagami Chem Res Center|Method for producing 1-substituted-5-fluoroalkylpyrazole-4-carboxylic acid ester|

---

US20110189167A1|2007-04-20|2011-08-04|Flynn Daniel L|Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases|

---

ES2423932T3|2007-08-27|2013-09-25|Basf Se|Pyrazole compounds to control invertebrate pests|

---

WO2009068652A1|2007-11-30|2009-06-04|Smithkline Beecham Corporation|2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators|

---

KR20110011652A|2008-05-05|2011-02-08|바스프 에스이|Method for preparing 1,3,4-substituted pyrazol compounds|

---

EA018198B1|2008-06-12|2013-06-28|Янссен Фармацевтика Нв|Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine hreceptor|

---

CN102224149B|2008-09-24|2014-09-10|巴斯夫欧洲公司|Pyrazole compounds for controlling invertebrate pests|

---

US8853125B2|2008-09-24|2014-10-07|Basf Se|Pyrazole compounds for controlling invertebrate pests|

---

US20100113465A1|2008-10-30|2010-05-06|Pfizer Inc.|7-azaspiro[3.5]nonane-7-carboxamide compounds|

---

EP2236505A1|2009-04-03|2010-10-06|Bayer CropScience AG|Acylated aminopyridines and pyridazines as insecticides|

---

AR076984A1|2009-06-08|2011-07-20|Merck Serono Sa|DERIVATIVES OF PIRAZOL OXADIAZOL|

---

BR112012006859A2|2009-09-29|2019-09-24|Glaxo Group Ltd|compounds|

---

JP2013529184A|2010-04-08|2013-07-18|ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング|Pharmaceutical combination containing a PDE4 inhibitor and an EP4 receptor antagonist|

---

EP2468736A1|2010-12-23|2012-06-27|LEK Pharmaceuticals d.d.|Synthesis of intermediates for preparing anacetrapib and derivates thereof|

---

WO2012098387A1|2011-01-18|2012-07-26|Centro Nacional De Investigaciones Oncológicas |6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors|

---

CN106420040B|2011-04-12|2020-08-28|热医学公司|Method and apparatus for heating fluid in fluid enhanced ablation therapy|

---

EA024737B1|2011-04-21|2016-10-31|Басф Се|Novel pesticidal pyrazole compounds|

---

WO2013004984A1|2011-07-07|2013-01-10|Centro Nacional De Investigaciones Oncologicas |Tricyclic compounds for use as kinase inhibitors|

---

WO2013142269A1|2012-03-19|2013-09-26|Envivo Pharmaceuticals, Inc.|Imidazotriazinone compounds|

---

JO3407B1|2012-05-31|2019-10-20|Eisai R&D Man Co Ltd|Tetrahydropyrazolopyrimidine Compounds|

---

EP2671873A1|2012-06-06|2013-12-11|Solvay Sa|Method for the cyclization of hydrazinoacrylic acid derivatives|

---

CN104703982B|2012-06-20|2018-01-05|巴斯夫欧洲公司|Pyrazole compound and the pesticide combination comprising pyrazole compound|

---

WO2014089364A1|2012-12-06|2014-06-12|Quanticel Pharmaceuticals, Inc|Histone demethylase inhibitors|

---

SI2938615T1|2012-12-14|2017-02-28|Pfizer Limited|Imidazopyridazine derivatives as gabaa receptor modulators|

---

ES2707751T3|2014-01-31|2019-04-04|Basf Se|Pyrazoles to control invertebrate pests|

---

WO2015162133A1|2014-04-22|2015-10-29|Basf Se|C3-c4-cycloalkenyl-comprising pyrazoles for controlling invertebrate pests|

---

WO2015169734A1|2014-05-05|2015-11-12|Basf Se|Pyrazoles for controlling invertebrate pests|

---

WO2015189080A1|2014-06-12|2015-12-17|Basf Se|Pesticidally active mixtures|

---

PT3174858T|2014-07-31|2019-07-23|Basf Se|Process for preparing pyrazoles|

---

WO2016128239A1|2015-02-11|2016-08-18|Basf Se|Pesticidal mixture comprising a pyrazole compound and a biopesticide|

---

WO2016128240A1|2015-02-11|2016-08-18|Basf Se|Pesticidal mixture comprising a pyrazole compound and two fungicides|

---

CA2975183A1|2015-02-11|2016-08-18|Basf Se|Pesticidal mixture comprising a pyrazole compound, an insecticide and a fungicide|

---

WO2016180833A1|2015-05-11|2016-11-17|Basf Se|Process for preparing 4-amino-pyridazines|

---

CN108699003A|2016-02-02|2018-10-23|巴斯夫欧洲公司|Prepare the catalytic hydrogenation of pyrazoles|US10093634B2|2013-12-18|2018-10-09|BASF Agro B.V.|Process for the preparation of substituted phenoxyphenyl ketones|

---

PT3174858T|2014-07-31|2019-07-23|Basf Se|Process for preparing pyrazoles|

---

CN107108647A|2014-10-24|2017-08-29|巴斯夫欧洲公司|Substituted pyridine compound with activity of weeding|

---

WO2016180642A1|2015-05-08|2016-11-17|BASF Agro B.V.|A process for the preparation of terpinolene epoxide|

---

DK3294700T3|2015-05-08|2020-04-14|Basf Agro Bv|PROCEDURE FOR PREPARING LIMONEN-4 OL|

---

WO2016180833A1|2015-05-11|2016-11-17|Basf Se|Process for preparing 4-amino-pyridazines|

---

CN107846896A|2015-08-07|2018-03-27|巴斯夫欧洲公司|The insect in corn is prevented and treated by ginkgolides and Bilobalide|

---

CN108699003A|2016-02-02|2018-10-23|巴斯夫欧洲公司|Prepare the catalytic hydrogenation of pyrazoles|

---

EP3472139B1|2016-06-15|2021-04-07|BASF Agro B.V.|Process for the epoxidation of a tetrasubstituted alkene|

---

CN109311835A|2016-06-15|2019-02-05|巴斯夫农业公司|The method of four substituted olefine of epoxidation|

---

EP3481795A1|2016-07-07|2019-05-15|Basf Se|Oxy-cope rearrangement for the manufacture of insecticidal cyclopentene compounds|

---

CA3050864A1|2017-01-26|2018-08-02|Mitsui Chemicals Agro, Inc.|Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients|

---

CA3059702A1|2017-04-10|2018-10-18|Mitsui Chemicals Agro, Inc.|Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients|

---

CA3059675A1|2017-04-10|2018-10-18|Mitsui Chemicals Agro, Inc.|Pyridone compounds and agricultural and horticultural fungicides comprising the same as active ingredients|

---

KR20190138772A|2017-04-11|2019-12-16|미쓰이가가쿠 아그로 가부시키가이샤|Pyridone Compounds and Agricultural Horticultural Fungicides|

---

CA3066591A1|2017-06-08|2018-12-13|Mitsui Chemicals Agro, Inc.|Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients|

---

EP3728198A1|2017-12-22|2020-10-28|Solvay Sa|Process for the manufacture of pyrazole carboxylic derivatives and precursors thereof|

---

TW202012388A|2018-07-25|2020-04-01|日商三井化學Agro股份有限公司|Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients|

法律状态:
2019-07-30| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-03-16| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-05-04| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/07/2015, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

EP14179249.9|2014-07-31|

---

EP14179249|2014-07-31|

---

PCT/EP2015/067507|WO2016016369A1|2014-07-31|2015-07-30|Process for preparing pyrazoles|

---